var title_f34_48_35584="Budesonide: Pediatric drug information";
var content_f34_48_35584=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Budesonide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12644918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/35/42547?source=see_link\">",
"       Budesonide (nasal): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/36/21064?source=see_link\">",
"       Budesonide (systemic therapy and oral inhalation): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13096 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-AA8FF843F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_48_35584=[""].join("\n");
var outline_f34_48_35584=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/35/42547?source=related_link\">",
"      Budesonide (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/36/21064?source=related_link\">",
"      Budesonide (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_48_35585="Progressive Cushings obesity";
var content_f34_48_35585=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F82114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F82114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    Progressive obesity in Cushing's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 158px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sequence of pictures in a boy with Cushing's disease. Panel A: Age six years, before apparent onset of Cushing's syndrome. Panel B: Age seven years, still with little evidence of cushingoid appearance. Panel C: Age eight years, with early facial rounding. Panel D: Age nine years, with \"moon\" facies. Panel E: Age 11 years, with florid Cushing's disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Williams Textbook of Endocrinology, 8th ed, Foster, DW, Wilson, JD (Eds), WB Saunders, Philadelphia, 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_48_35585=[""].join("\n");
var outline_f34_48_35585=null;
var title_f34_48_35586="Horizontal arm traction";
var content_f34_48_35586=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F71579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F71579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Horizontal arm traction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In horizontal arm traction, the arm is flexed across the anterior chest, and steady, prolonged traction is applied in a horizontal direction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_48_35586=[""].join("\n");
var outline_f34_48_35586=null;
var title_f34_48_35587="RTH hormonal response";
var content_f34_48_35587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 585px\">",
"   <div class=\"ttl\">",
"    Pituitary and peripheral tissues responses to the administration of T3 in RTH",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 565px; height: 687px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Responses to the administration of incremental doses of L-T3 in three representative subjects: with RTH due to TR",
"    <sub>",
"     &beta;",
"    </sub>",
"    gene mutation (left), RTH without a mutation in the TR genes (nonTR RTH, right) and a normal individual (center). The hormone was given in three incremental doses, each for 3 days. A) Thyrotroph responses to TSH-releasing hormone (TRH) stimulation. Compared to normal, TSH responses are less suppressible by L-T3. B) Peripheral tissues responses. Note the stimulation of ferritin and sex hormone binding globulin (SHBG) and the suppression of cholesterol and creatine kinase (CK) in the normal subject. Responses in affected subjects, with or without a TR",
"    <sub>",
"     &beta;",
"    </sub>",
"    gene mutation, were blunted or paradoxical.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: WWW.THYROIDMANAGER.ORG, the comprehensive free on-line web text-book, Chapter 16d, by Samuel Refetoff, MD, version 7 June 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_48_35587=[""].join("\n");
var outline_f34_48_35587=null;
var title_f34_48_35588="Histopathology rabies";
var content_f34_48_35588=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Histopathological findings in a patient with rabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 194px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histopathologic examination of CNS tissue from autopsy showing neuronal cytoplasmic inclusions (Negri bodies) after hematoxylin and eosin staining (left) and rabies virus antigen (red) after immunohistochemical staining (right).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention. Human Rabies---Kentucky/Indiana, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:393.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_48_35588=[""].join("\n");
var outline_f34_48_35588=null;
var title_f34_48_35589="Vestibular system PI";
var content_f34_48_35589=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F52509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F52509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    The vestibular system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 652px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Deep inside the ear there is a small network of tubes that are filled with fluid, called the \"semicircular canals.\" Special membranes with calcium crystals on them are called \"otolith organs.\" Together, these tubes and membranes make up the \"vestibular system.\" This system tells the brain what position the body is in. It also helps keep you balanced.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_48_35589=[""].join("\n");
var outline_f34_48_35589=null;
var title_f34_48_35590="Management of infertility and pregnancy in women of advanced age";
var content_f34_48_35590=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of infertility and pregnancy in women of advanced age",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/48/35590/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/48/35590/contributors\">",
"     Ruth C Fretts, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/48/35590/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/48/35590/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/48/35590/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/48/35590/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/48/35590/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All women of reproductive age should receive preconception counseling since many pregnancies are unplanned and thus may occur under less than optimal conditions (eg, poorly controlled diabetes, exposure to teratogens). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/25/16794?source=see_link\">",
"     \"Preconception evaluation and counseling\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women who delay childbearing are at increased risk of infertility and certain pregnancy complications. Providing information to all patients of child-bearing age about the obstetrical risks of advanced maternal age can help them make informed decisions about the timing of child-bearing.",
"   </p>",
"   <p>",
"    Women should know that the probability of achieving a pregnancy begins to decline significantly at about age 32 and that coexisting medical disease and pregnancy complications become more common with advancing age. These complications include ectopic pregnancy, spontaneous abortion, fetal chromosomal abnormalities, some congenital anomalies, placenta previa, gestational diabetes, preeclampsia, and cesarean delivery. Such complications may, in turn, result in preterm birth. There is also an increased risk of perinatal mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31865?source=see_link\">",
"     \"Effect of advanced age on fertility and pregnancy in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These risks should be balanced against career and other personal issues that might favor delaying pregnancy. There are, however, a few advantages to delayed childbearing. As an example, older couples tend to be more emotionally mature and financially stable than when they were younger.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION OF FERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many experts suggest initiating a fertility evaluation after six months of unprotected intercourse without conception in women 35 to 40 years of age, and immediate evaluation in women over 40 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Evaluation is also initiated sooner than six months if the female partner has a history of",
"    <span class=\"nowrap\">",
"     oligomenorrhea/amenorrhea,",
"    </span>",
"    pelvic infection, pelvic surgery, chemotherapy, radiation therapy, or endometriosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40921?source=see_link\">",
"     \"Evaluation of female infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OPTIONS FOR TREATMENT OF INFERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expectant management of age-related infertility is an option for couples who do not desire medical intervention. Options for active intervention include controlled ovarian stimulation with intrauterine insemination (IUI), in vitro fertilization (IVF), and oocyte donation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25496?source=see_link\">",
"     \"Unexplained infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24807?source=see_link\">",
"     \"Oocyte donation for assisted reproduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both controlled ovarian stimulation with IUI and IVF can improve the likelihood of achieving pregnancy in the months when they are employed, but they do not improve oocyte quality and cannot compensate for all of the effects of the age-related decline in natural fertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients who undertake these therapies should be informed of the increased risk of multiple gestation, including the economic and psychological impact of raising children of a multiple gestation. Adverse pregnancy outcomes associated with use of ART should also be reviewed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/6/2154?source=see_link\">",
"     \"Pregnancy outcome after assisted reproductive technology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10819180\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the low probability of achieving pregnancy with controlled ovarian",
"    <span class=\"nowrap\">",
"     stimulation/IUI",
"    </span>",
"    in women over &gt;40 and &lt;43 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], we suggest offering IVF as the first-line option [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/6\">",
"     6",
"    </a>",
"    ]. However, insurance coverage may require a trial of one or two cycles of controlled ovarian hyperstimulation plus IUI prior to attempting IVF. Insurance coverage sometimes dictates an algorithm of available services based on maternal age, day 3 FSH testing, and any additional male factor issues. Some couples without insurance coverage for fertility treatment may only be able to afford the less expensive option of controlled ovarian hyperstimulation plus IUI.",
"   </p>",
"   <p>",
"    For women &gt;43 years, we suggest offering IVF using oocytes from a young donor. Controlled ovarian",
"    <span class=\"nowrap\">",
"     stimulation/IUI",
"    </span>",
"    is not effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/4\">",
"     4",
"    </a>",
"    ] and the IVF success rate with the woman&rsquo;s own oocytes is very low (&lt;5 percent live birth per cycle) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/6\">",
"     6",
"    </a>",
"    ], whereas IVF success with donor oocytes is very high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. For women &gt;40 and &lt;43 years of age who choose to undergo IVF with their own eggs, the first cycle will provide data to guide future decision-making. If the ovarian response is poor, she may desire to move to IVF using donor oocytes. If the ovarian response and embryo development are good, she may prefer to try two or three cycles of IVF before considering IVF using donor oocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Controlled ovarian stimulation and intrauterine insemination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The negative effect of older age on success of controlled ovarian stimulation and IUI was illustrated in a large single center review of pregnancy outcome in 168 consecutive women aged &ge;40 years who underwent ovulation induction plus IUI (total of 469 cycles) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/4\">",
"     4",
"    </a>",
"    ]. The proportion of women aged 40, 41, and 42 years who became pregnant was 9.6, 5.2, and 2.4 percent per cycle, respectively, with no viable pregnancies occurring in women aged &ge;43 years.",
"   </p>",
"   <p>",
"    In addition, a life-table analysis of 751 IUI cycles found that fecundability in women 19 to 35 years of age ranged from 17 to 30 percent, but fell to 13 percent in women 35 to 39 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25496?source=see_link&amp;anchor=H9#H9\">",
"     \"Unexplained infertility\", section on 'Intrauterine insemination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     In vitro fertilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success of IVF using fresh nondonor eggs is lower for women in their late 30s and early 40s than for women under 35 years of age (",
"    <a class=\"graphic graphic_figure graphicRef50854 \" href=\"mobipreview.htm?11/47/12031\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/8\">",
"     8",
"    </a>",
"    ]. As her age increases, a woman's chance of progressing from the beginning of ART to pregnancy and live birth (using her own eggs) decreases at every stage of ART. Data from a national registry showed that 41.7 percent of cycles started among women younger than 35 years of age resulted in live births, but this rate was only 31.9 percent among women 35 to 37 years of age, 22.1 percent among women 38 to 40, 12.5 percent among women 41 to 42, and 4.1 percent among women older than 42 (",
"    <a class=\"graphic graphic_figure graphicRef58270 graphicRef62286 \" href=\"mobipreview.htm?36/25/37266\">",
"     figure 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Oocyte donation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oocyte donation is the only effective option for women over age 40 who have diminished ovarian reserve (",
"    <a class=\"graphic graphic_figure graphicRef50854 \" href=\"mobipreview.htm?11/47/12031\">",
"     figure 1",
"    </a>",
"    ). The risk of chromosomal abnormality in offspring correlates with the age of the oocyte donor, whereas the risks of pregnancy complications, such as gestational diabetes and hypertension, are consistent with the age of the recipient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The success of egg donation does not significantly vary according to the recipient's age up to age 50, after which there may be a small decline due to lower rates of implantation (",
"    <a class=\"graphic graphic_figure graphicRef82403 \" href=\"mobipreview.htm?37/4/37967\">",
"     figure 3",
"    </a>",
"    ). In the largest study of delivery outcomes in recipients of donated eggs, implantation rates (#fetal heart",
"    <span class=\"nowrap\">",
"     beats/#",
"    </span>",
"    of embryos transferred) with fresh egg donation in women &le;49 years of age (n = 13,000 egg donations) versus age 50 to 54 (n = 300 egg donations) were 22 and 16 percent, respectively, and the delivery rates (live",
"    <span class=\"nowrap\">",
"     birth/retrieval)",
"    </span>",
"    were 40 and 32 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24807?source=see_link\">",
"     \"Oocyte donation for assisted reproduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no accepted standards for the upper age limit for childbearing in the United States, although such standards exist in other countries. A practice on",
"    <span class=\"nowrap\">",
"     gamete/embryo",
"    </span>",
"    donation by the American Society for Reproductive Medicine (ASRM) recommends that all potential recipients of oocyte donation over the age of 45 undergo thorough medical evaluation including cardiovascular testing and a high-risk obstetric consultation before beginning treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, a statement from the ASRM Ethics Committee discourages oocyte donation to postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/11\">",
"     11",
"    </a>",
"    ]. The ASRM has also stated that patients and programs should determine on a case-by-case basis whether a woman's health, medical and genetic risks, and child rearing capability justify proceeding with treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cryopreservation to preserve fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who are approaching advanced reproductive age, but are not ready to become pregnant or are not in the position to have a child, options to preserve fertility, including embryo and oocyte cryopreservation, may be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/61/18392?source=see_link\">",
"     \"Fertility preserving options for women of advancing age\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREGNANCY MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific issues should be addressed with the older gravida, in addition to routine prenatal assessments. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42010?source=see_link\">",
"     \"Initial prenatal assessment and patient education\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following suggestions apply to women &ge;35 years of age at the estimated date of delivery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of fetal aneuploidy based on maternal age should be reviewed (",
"      <a class=\"graphic graphic_table graphicRef70032 \" href=\"mobipreview.htm?37/3/37947\">",
"       table 1",
"      </a>",
"      ). Most data relate to risk of trisomy 21 or composite risk of any aneuploidy, but some data are also available for maternal age-specific prevalence of trisomies 13 and 18 for women aged 16&ndash;45 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/12\">",
"       12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There are two approaches to identifying fetal aneuploidy: (1) invasive testing (amniocentesis, chorionic villus sampling), which is diagnostic, and (2) screening using maternal serum testing and ultrasonographic evaluation of fetal nuchal translucency to adjust the mother's age related risk. Women whose screening test suggests a high risk of aneuploidy could choose to undergo diagnostic invasive testing, while those at low risk might choose to avoid invasive testing because of the small, but non-zero risk of procedure-related pregnancy loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16570?source=see_link&amp;anchor=H17#H17\">",
"       \"Diagnostic amniocentesis\", section on 'Complications and adverse outcomes'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Down syndrome screening tests have both higher detection rates and higher false positive rates in older women than in younger women because of the higher prevalence of Down syndrome in offspring of older women (",
"      <a class=\"graphic graphic_table graphicRef75847 \" href=\"mobipreview.htm?38/57/39835\">",
"       table 2",
"      </a>",
"      ). A variety of screening tests are available. In a mathematical model, the detection rate for Down syndrome using contingent screening was comparable with step-wise and integrated screening for a fixed false-positive rate, but substantially reduced the number needing to return for second trimester testing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/27/22969?source=see_link\">",
"       \"Overview of prenatal screening and diagnosis of Down syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22170?source=see_link\">",
"       \"Sonographic findings associated with fetal aneuploidy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Age and obesity are risk factors for development of type 2 diabetes mellitus, as well as gestational diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/15\">",
"       15",
"      </a>",
"      ]. Since type 2 diabetes may not have been recognized periconceptionally, screening older obese gravida for gestational diabetes in the first trimester, as well as later in pregnancy, is reasonable.",
"     </li>",
"     <li>",
"      Given the increased risk of congenital anomalies in older women, we feel a detailed second trimester ultrasound examination to look for significant structural anomalies (particularly cardiac defects) is reasonable. The cost-effectiveness of this approach, however, has not been proven. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31865?source=see_link&amp;anchor=H10#H10\">",
"       \"Effect of advanced age on fertility and pregnancy in women\", section on 'Congenital malformations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43576?source=see_link\">",
"       \"Routine prenatal ultrasonography as a screening tool\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clinician should discuss pregnancy complications that occur with increased frequency in older gravidae, such as spontaneous abortion, some congenital anomalies, placenta previa, gestational diabetes, preeclampsia, and cesarean delivery. Some of these complications may, in turn, result in preterm birth, so the implications of preterm birth should also be reviewed.",
"     </li>",
"     <li>",
"      The patient's risk for adverse outcome, including preterm",
"      <span class=\"nowrap\">",
"       delivery/low",
"      </span>",
"      birth weight, intrauterine growth restriction, and stillbirth, should be assessed by considering not only her age, but also the presence or absence of concomitant risk factors such as hypertension, diabetes, obesity, low socioeconomic status, black race, and previous pregnancy complicated by growth restriction or preterm birth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no large randomized trials that have examined the efficacy of routine antepartum testing or timed delivery in this population. A randomized trial is unlikely to be undertaken to address this question and there remains no consensus on the management of late pregnancy in women of advanced maternal age. One strategy is to stratify women based on their risk factors, such as age and parity, and to consider other factors that might influence risk, such as pregestational obesity and race [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/16\">",
"     16",
"    </a>",
"    ]. The risks associated with age and parity were illustrated in a population-based study that found the risk of stillbirth after 37 weeks of gestation in primiparous and multiparous women less than 35 years of age was",
"    <span class=\"nowrap\">",
"     1/270",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     1/775,",
"    </span>",
"    respectively; for women 35 to 39 years of age, it was",
"    <span class=\"nowrap\">",
"     1/156",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     1/502,",
"    </span>",
"    respectively; and for women 40 years of age or older, it was",
"    <span class=\"nowrap\">",
"     1/116",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     1/304,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/17\">",
"     17",
"    </a>",
"    ]. The highest risk was in black women over the age of 40. These results provide support for managing older women as \"post-term\" earlier in gestation than younger women.",
"   </p>",
"   <p>",
"    We emphasize the importance of fetal movement as a sign of fetal well-being and encourage all of our patients to perform kick counts and report decreased fetal movement in a timely fashion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15959?source=see_link\">",
"     \"Evaluation of decreased fetal movements\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We also discuss the pros and cons of increased vigilance late in pregnancy, including a discussion of the lack of strong evidence for antepartum fetal testing and the possible risk of an increased rate of induction in women who undergo this testing. In a decision analysis, weekly antepartum testing initiated at 37 weeks in nulliparous women age &ge;35 would avert 3.9 fetal deaths per 1000 pregnancies, but would require 863 antepartum tests, 71 inductions, and 14 additional cesarean deliveries per fetal death averted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimum time for delivery is unclear. A retrospective cohort study suggested that, in women of advanced maternal age, the optimum time for delivery was between",
"    <span class=\"nowrap\">",
"     38",
"     <sup>",
"      5/7th",
"     </sup>",
"    </span>",
"    weeks to",
"    <span class=\"nowrap\">",
"     39",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35590/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For women 40 years of age or older, we generally obtain an ultrasound examination at 38 to 39 weeks of gestation to assess fetal growth and amniotic fluid volume, and then offer twice weekly antepartum testing, alternating between a nonstress test and a biophysical profile. We favor delivery at 39 weeks of gestation, given their increased risk of stillbirth and the diminishing reproductive options for women at this age. However, we discuss both the option of induction and that of ongoing surveillance with these women, and respect the patient's preference regarding timing and type of intervention.",
"   </p>",
"   <p>",
"    Our testing strategy for women 35 to 39 years of age depends on whether the patient has any additional risk factors for stillbirth, such as black race and pre-pregnancy obesity. As discussed above, we offer delivery at 39 weeks of gestation, given the increased risk of stillbirth and the diminishing reproductive opportunities for women at this age, but discuss both the option of induction at term or ongoing surveillance and respect the patient's preference. For women who prefer expectant management at 39 weeks, we perform twice weekly antepartum testing and&nbsp;ask the women to monitor daily fetal movement (kick counts). In addition, women who are nulliparous and 39 years of age are counseled differently from multiparous women who are 35 years of age since the underlying risks of stillbirth are higher in the nulliparous older woman than in multiparous younger woman.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women should be informed that delaying childbearing until the mid 30s significantly increases the risk of infertility and of developing a chronic medical disease which might complicate pregnancy. Pregnancy complications that occur with increased frequency in older gravidae include: ectopic pregnancy, spontaneous abortion, fetal chromosomal abnormalities, some congenital anomalies, placenta previa, gestational diabetes, preeclampsia, and cesarean delivery. Such complications may, in turn, result in preterm birth. There is also an increased risk of perinatal mortality. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Experts suggest initiating a fertility evaluation after six months of unprotected intercourse without conception in women 35 to 40 years of age, and immediate evaluation in women over 40 years of age. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation of fertility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fertility treatments cannot compensate for all of the effects of the age-related decline in natural fertility and these treatments are associated with maternal and fetal risks. Oocyte donation is the only effective option for women over age 40 with diminished ovarian reserve. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Options for treatment of infertility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women over &gt;40 and &lt;43 years, we suggest offering IVF as the first-line option (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For women &gt;43 years, we suggest offering IVF using oocytes from a young donor as a first-line approach (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10819180\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnant women &ge;35 years of age at the estimated date of delivery, we suggest offering prenatal diagnosis or screening for aneuploidy and a detailed second trimester ultrasound examination (18 to 20 weeks of gestation) to look for significant structural anomalies (particularly cardiac defects (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      )). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pregnancy management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We routinely ask older women to perform fetal kick counts, but limit nonstress testing and ultrasound assessment of fetal well-being to women with additional risk factors for fetal compromise. We consider women age 40 years or older to be biologically \"postterm\" at 39 weeks of gestation, and suggest they undergo induction at 39 weeks of gestation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We also discuss the alternative of ongoing close fetal and maternal surveillance, and respect the patient's preference regarding timing and type of intervention. However, we generally discourage expectant management with close surveillance beyond 40 weeks of gestation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pregnancy management'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35590/abstract/1\">",
"      Practice Committee of the American Society for Reproductive Medicine. Aging and infertility in women: a committee opinion. Fertil Steril 2002; 78:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35590/abstract/2\">",
"      American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Age-related fertility decline. Obstet Gynecol 2008; 112:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35590/abstract/3\">",
"      Leridon H. Can assisted reproduction technology compensate for the natural decline in fertility with age? A model assessment. Hum Reprod 2004; 19:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35590/abstract/4\">",
"      Corsan G, Trias A, Trout S, Kemmann E. Ovulation induction combined with intrauterine insemination in women 40 years of age and older: is it worthwhile? Hum Reprod 1996; 11:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35590/abstract/5\">",
"      Stovall DW, Toma SK, Hammond MG, Talbert LM. The effect of age on female fecundity. Obstet Gynecol 1991; 77:33.",
"     </a>",
"    </li>",
"    <li>",
"     SART. National Data Summary Report. www.sartcorsonline.com/rptCSR_PublicMultYear.aspx?ClinicPKID=0 (Accessed on May 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35590/abstract/7\">",
"      Toner JP, Grainger DA, Frazier LM. Clinical outcomes among recipients of donated eggs: an analysis of the U.S. national experience, 1996-1998. Fertil Steril 2002; 78:1038.",
"     </a>",
"    </li>",
"    <li>",
"     American Society for Reproductive Medicine a Practice Committee Report A Committee Opinion Aging and Infertility in Women. January 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35590/abstract/9\">",
"      Krieg SA, Henne MB, Westphal LM. Obstetric outcomes in donor oocyte pregnancies compared with advanced maternal age in in vitro fertilization pregnancies. Fertil Steril 2008; 90:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35590/abstract/10\">",
"      Practice Committee of American Society for Reproductive Medicine, Practice Committee of Society for Assisted Reproductive Technology. 2008 Guidelines for gamete and embryo donation: a Practice Committee report. Fertil Steril 2008; 90:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35590/abstract/11\">",
"      Ethics Committee of the American Society for Reproductive Medicine. Oocyte donation to postmenopausal women. Fertil Steril 2004; 82 Suppl 1:S254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35590/abstract/12\">",
"      Savva GM, Walker K, Morris JK. The maternal age-specific live birth prevalence of trisomies 13 and 18 compared to trisomy 21 (Down syndrome). Prenat Diagn 2010; 30:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35590/abstract/13\">",
"      Benn PA, Egan JF, Fang M, Smith-Bindman R. Changes in the utilization of prenatal diagnosis. Obstet Gynecol 2004; 103:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35590/abstract/14\">",
"      Cuckle HS, Malone FD, Wright D, et al. Contingent screening for Down syndrome--results from the FaSTER trial. Prenat Diagn 2008; 28:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35590/abstract/15\">",
"      Solomon CG, Willett WC, Carey VJ, et al. A prospective study of pregravid determinants of gestational diabetes mellitus. JAMA 1997; 278:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35590/abstract/16\">",
"      Reddy UM, Laughon SK, Sun L, et al. Prepregnancy risk factors for antepartum stillbirth in the United States. Obstet Gynecol 2010; 116:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35590/abstract/17\">",
"      Reddy UM, Ko CW, Willinger M. Maternal age and the risk of stillbirth throughout pregnancy in the United States. Am J Obstet Gynecol 2006; 195:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35590/abstract/18\">",
"      Fretts RC, Elkin EB, Myers ER, Heffner LJ. Should older women have antepartum testing to prevent unexplained stillbirth? Obstet Gynecol 2004; 104:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35590/abstract/19\">",
"      Nicholson JM, Kellar LC, Kellar GM. The impact of the interaction between increasing gestational age and obstetrical risk on birth outcomes: evidence of a varying optimal time of delivery. J Perinatol 2006; 26:392.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 454 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-ECB61E16A9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_48_35590=[""].join("\n");
var outline_f34_48_35590=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION OF FERTILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OPTIONS FOR TREATMENT OF INFERTILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10819180\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Controlled ovarian stimulation and intrauterine insemination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Oocyte donation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cryopreservation to preserve fertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREGNANCY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/454\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/454|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/47/12031\" title=\"figure 1\">",
"      Live births per embryo transfer by maternal age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/29/31199\" title=\"figure 2A\">",
"      Outcomes of ART by stage of procedure and maternal age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/6/6255\" title=\"figure 2B\">",
"      Pregnancy rates with ART at maternal age 40 and older",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/4/37967\" title=\"figure 3\">",
"      ART outcome in women age 50 and older using donor eggs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/454|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/3/37947\" title=\"table 1\">",
"      Percent pregnancy loss by maternal age at conception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/57/39835\" title=\"table 2\">",
"      Performance of Down syndrome screening tests by maternal age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31865?source=related_link\">",
"      Effect of advanced age on fertility and pregnancy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15959?source=related_link\">",
"      Evaluation of decreased fetal movements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40921?source=related_link\">",
"      Evaluation of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/61/18392?source=related_link\">",
"      Fertility preserving options for women of advancing age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/14/24807?source=related_link\">",
"      Oocyte donation for assisted reproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/27/22969?source=related_link\">",
"      Overview of prenatal screening and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/25/16794?source=related_link\">",
"      Preconception evaluation and counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/6/2154?source=related_link\">",
"      Pregnancy outcome after assisted reproductive technology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43576?source=related_link\">",
"      Routine prenatal ultrasonography as a screening tool",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22170?source=related_link\">",
"      Sonographic findings associated with fetal aneuploidy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25496?source=related_link\">",
"      Unexplained infertility",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_48_35591="Eosinophilic folliculitis B";
var content_f34_48_35591=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54404%7EDERM%2F87125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54404%7EDERM%2F87125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic folliculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    HIV-associated eosinophilic folliculitis is characterized by recurrent, pruritic crops of discrete, erythematous, urticarial follicular papules and rare pustules, with a diameter of 3 to 5 mm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Toby Maurer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    HIV-associated eosinophilic folliculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules and excoriated papules are present on the back.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_48_35591=[""].join("\n");
var outline_f34_48_35591=null;
var title_f34_48_35592="Pulmonary Langerhans cell histiocytosis";
var content_f34_48_35592=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary Langerhans cell histiocytosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/48/35592/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/48/35592/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/48/35592/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/48/35592/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/48/35592/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/48/35592/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/48/35592/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary Langerhans cell histiocytosis (PLCH), also called eosinophilic granuloma of the lung, pulmonary Langerhans cell granulomatosis, and pulmonary histiocytosis X, is an uncommon interstitial lung disease that primarily affects young adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The true incidence and prevalence are unknown. However, the diagnosis is made in less than 5 percent of lung biopsies and has been seen in less than 2 percent of the patients presenting to the Denver Specialized Center of Research program in Interstitial Lung Disease (a total of approximately 3000 patients over 14 years). No occupational or geographic predisposition has been reported, but nearly all affected individuals have a history of current or prior cigarette smoking. Thus, tobacco smoke is thought to be an etiologic factor.",
"   </p>",
"   <p>",
"    Pulmonary Langerhans cell histiocytosis will be reviewed here. A general review of Langerhans cell histiocytosis, including the extrapulmonary manifestations of this disorder, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Langerhans cell, a differentiated cell of the monocyte-macrophage line, is the pathologic cell type of pulmonary Langerhans cell histiocytosis. It is distinguished by pale staining cytoplasm, a large nucleus and nucleoli, and, on electron microscopy, by classic pentalaminar cytoplasmic inclusions or Birbeck granules (X-bodies, (",
"    <a class=\"graphic graphic_picture graphicRef60620 \" href=\"mobipreview.htm?2/32/2570\">",
"     picture 1",
"    </a>",
"    )). Langerhans cells also demonstrate positive immunohistochemical staining for S100 protein. Another characteristic is the strong presence of CD1 antigen (CD1a) on the cell surface, a feature not observed in other cells of histiocytic origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Langerhans cells are normally found in the dermis, the reticuloendothelial system, the lung, and the pleura. They can be found in association with cigarette smoking in otherwise healthy individuals and can also be seen in other pulmonary disorders, such as idiopathic pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/39/32378?source=see_link\">",
"     \"Pathogenesis of idiopathic pulmonary fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In pulmonary Langerhans cell histiocytosis, the Langerhans cells are characteristically found in clusters and significantly outnumber those seen in other lung diseases. However, quantitative guidelines for the diagnosis of pulmonary Langerhans cell histiocytosis have not been established.",
"   </p>",
"   <p>",
"    Early inflammatory lesions surround the smaller bronchioles and usually contain an admixture of eosinophils, lymphocytes, and neutrophils (",
"    <a class=\"graphic graphic_picture graphicRef55413 \" href=\"mobipreview.htm?26/25/27029\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/8\">",
"     8",
"    </a>",
"    ]. However, since eosinophils are not a prominent part of the pathology and the lesions are often devoid of eosinophils, the older term eosinophilic granuloma is a misnomer. These lesions may also involve pulmonary arterioles and venules (",
"    <a class=\"graphic graphic_picture graphicRef58695 \" href=\"mobipreview.htm?27/41/28308\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three other pathologic features that may be seen in pulmonary Langerhans cell histiocytosis have been reemphasized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pseudo-desquamative interstitial pneumonia (DIP), characterized by the accumulation of alveolar macrophages in the pulmonary parenchyma in between the typical lesions containing Langerhans cells. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4474?source=see_link&amp;anchor=H7#H7\">",
"       \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\", section on 'Desquamative interstitial pneumonia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Respiratory (\"smokers\") bronchiolitis, characterized by pigmented macrophages filling the lumen of bronchioles and the surrounding alveolar spaces. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34633?source=see_link\">",
"       \"Respiratory bronchiolitis-associated interstitial lung disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intraluminal fibrosis, characterized by mural incorporation, alveolar obliteration, and intraluminal buds. This finding supports the hypothesis that intraluminal fibrosis is a mechanism for alveolar collapse with progression to interstitial fibrosis and lung remodeling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is often a predominance of disease in the mid to upper zones of the lung, in contrast to the typical lower zone predominance of idiopathic pulmonary fibrosis. Lesions frequently extend widely into the parenchyma of the lung surrounding the bronchovascular structures, producing the so-called",
"    <strong>",
"     stellate lesions",
"    </strong>",
"    that are characteristic of this disorder (",
"    <a class=\"graphic graphic_picture graphicRef52774 graphicRef71884 graphicRef51661 \" href=\"mobipreview.htm?40/54/41834\">",
"     picture 4A-C",
"    </a>",
"    ). Interstitial fibrosis and small cyst formation occur with advancing disease; the mechanism for cyst formation is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older histopathological lesions can be relatively acellular. As a result, the eventual diffuse interstitial pathology can be difficult to distinguish from other forms of end-stage pulmonary fibrosis, with extensive areas of fibrosis and honeycombing accompanied by cystic lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of pulmonary Langerhans cell histiocytosis is unknown. Several abnormalities in immune function have been found, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A nonspecific increase in IgG in bronchoalveolar lavage fluid",
"     </li>",
"     <li>",
"      Immune complexes in the circulation and bound to tissue",
"     </li>",
"     <li>",
"      Abnormalities in T-cell function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although it is possible that these factors may be important in the pathophysiology of pulmonary Langerhans cell histiocytosis, they may also represent nonspecific generalized activation of immune effector cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Role of cigarette smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;The near universal association of PLCH with cigarette smoking strongly implies some causative role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast, there does",
"    <strong>",
"     not",
"    </strong>",
"    appear to be an association of smoking with extrapulmonary Langerhans cell histiocytosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One hypothesis is that increased bombesin-like peptide production plays a central role (",
"      <a class=\"graphic graphic_figure graphicRef57136 \" href=\"mobipreview.htm?27/9/27805\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/15\">",
"       15",
"      </a>",
"      ]. Bombesin is a neuropeptide produced by neuroendocrine cells, which are increased in the lungs of smokers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/16\">",
"       16",
"      </a>",
"      ]. Bombesin-like peptides are chemotactic for monocytes, mitogenic for epithelial cells and fibroblasts, and they stimulate cytokine secretion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/15,17\">",
"       15,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tobacco glycoprotein, a constituent of tobacco, is an immunostimulant that induces lymphocyte differentiation and lymphokine production. Tobacco glycoprotein and other regulatory glycopeptides (eg, GM-CSF) may contribute to disease pathogenesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Finally, PLCH may represent a reactive polyclonal process that is induced by antigens in cigarette smoke. This would distinguish it from the other systemic forms of Langerhans cell histiocytosis, which have been shown to be the result of a monoclonal proliferation of Langerhans cell [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of PLCH occur in young adults between 20 and 40 years of age (",
"    <a class=\"graphic graphic_figure graphicRef69932 \" href=\"mobipreview.htm?18/34/18989\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. There is an equal gender distribution, though women tend to present at an older age. Caucasians are affected more commonly than individuals of African or Asian descent. The duration of illness is usually less than one year prior to diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with PLCH present to medical attention in one of several ways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      With abnormalities incidentally detected on chest radiographs.",
"     </li>",
"     <li>",
"      Following a spontaneous pneumothorax.",
"     </li>",
"     <li>",
"      With respiratory or constitutional symptoms, especially fever or weight loss.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When patients present with symptoms, the most common symptoms include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/4,8,22,23\">",
"     4,8,22,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nonproductive cough (56 to 70 percent)",
"     </li>",
"     <li>",
"      Dyspnea (40 to 87 percent)",
"     </li>",
"     <li>",
"      Chest pain, which is frequently pleuritic (10 to 21 percent)",
"     </li>",
"     <li>",
"      Fatigue (approximately 30 percent)",
"     </li>",
"     <li>",
"      Weight loss (20 to 30 percent)",
"     </li>",
"     <li>",
"      Fever (15 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The physical examination is usually unremarkable. Crackles and digital clubbing are uncommonly found on examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]. Routine laboratory studies are usually unrevealing, and the peripheral eosinophil count is normal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/20/22856?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PLCH are at risk for a variety of thoracic and extrathoracic complications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent spontaneous pneumothorax occurs in 15 to 25 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/25\">",
"       25",
"      </a>",
"      ]. Pleural thickening or effusion is rarely seen in the absence of a previous pneumothorax.",
"     </li>",
"     <li>",
"      Pulmonary arteriopathy and veno-occlusive disease can occur independently from parenchymal and airway disease, and may impair diffusing capacity and exercise capacity to a degree disproportionate to radiographic findings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pulmonary hypertension appears to be common among patients with PLCH, even in the absence of overt symptoms of right heart failure. An echocardiographic study of patients with histologically proven PLCH noted a resting peak pulmonary artery pressure &ge;35 mmHg in 15 of 17 patients (88 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/27\">",
"     27",
"    </a>",
"    ]. The development of pulmonary hypertension was strongly associated with increased mortality, suggesting that severe pulmonary hypertension is not limited to patients with end-stage pulmonary disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemoptysis is occasionally reported (13 percent) and should prompt consideration of superimposed infection (eg, Aspergillus) or tumor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/23,28\">",
"       23,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A number of malignant and nonmalignant tumors have been found in association with pulmonary Langerhans cell histiocytosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/29-33\">",
"       29-33",
"      </a>",
"      ]. These include bronchogenic carcinoma (5 percent of patients), Hodgkin's and non-Hodgkin lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/33\">",
"       33",
"      </a>",
"      ], pulmonary carcinoid tumor, and mediastinal ganglioneuroma. The malignancy may precede, follow, or occur concomitantly with the diagnosis of pulmonary Langerhans cell histiocytosis. The carcinogenic effect of cigarette smoke is probably the cause of some of these tumors.",
"     </li>",
"     <li>",
"      Cystic bone lesions are present in 4 to 20 percent of patients and may produce localized pain or a pathologic bone fracture. Skeletal involvement may precede the more typical pulmonary manifestations, and may be the sole manifestation of Langerhans cell histiocytosis. The radiographic pattern on bone films is not diagnostic. In most instances, the lesions are solitary and involve the flat bones. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diabetes insipidus, secondary to hypothalamic involvement, is seen in approximately 15 percent of patients, and is believed to portend a worse prognosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of pulmonary Langerhans cell histiocytosis are nonspecific and often point to other, more common pulmonary diagnoses. However, a history of recurrent pneumothorax, diabetes insipidus, or bone pain can be helpful in suggesting the diagnosis. A current or past smoking history is a consistent (but not essential) historical feature.",
"   </p>",
"   <p>",
"    Most evaluations for pulmonary Langerhans cell histiocytosis are prompted after an abnormal chest roentgenogram is obtained. High resolution computed tomography (HRCT) of the chest, if classic, can be diagnostic, and therefore should be obtained in all patients suspected of having the disease. The differential diagnosis on chest CT scan includes pulmonary lymphangioleiomyomatosis, tuberous sclerosis, hypersensitivity pneumonitis, sarcoidosis, and endstage idiopathic pulmonary fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16681?source=see_link\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiographic appearance of pulmonary Langerhans cell histiocytosis can be very characteristic, if not diagnostic. A combination of the following features is felt to be highly specific for pulmonary Langerhans cell histiocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ill-defined or stellate nodules (2 to 10 mm in size)",
"     </li>",
"     <li>",
"      Reticulonodular opacities",
"     </li>",
"     <li>",
"      Upper zone cysts or honeycombing",
"     </li>",
"     <li>",
"      Preservation of lung volume",
"     </li>",
"     <li>",
"      Costophrenic angle sparing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reticulonodular opacities are typically seen in the middle to upper lung zones (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82197 \" href=\"mobipreview.htm?22/28/22980\">",
"     image 1",
"    </a>",
"    ). The total lung volume is normal, although both hyperinflation and reduced volume can occur (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60751 \" href=\"mobipreview.htm?10/14/10469\">",
"     image 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/23,37\">",
"     23,37",
"    </a>",
"    ]. Hilar or mediastinal adenopathy is rare and should prompt consideration of malignancy as a secondary diagnosis. Pleural thickening is most often due to treated pneumothorax. Bone lesions can occur in any bone, including the ribs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5096?source=see_link\">",
"     \"Evaluation of diffuse lung disease by conventional chest radiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-resolution computed tomography (HRCT) of the chest is a particularly useful diagnostic tool in patients with suspected PLCH. The combination of multiple cysts and nodules, with a mid to upper zone predominance, and interstitial thickening in a young smoker is so characteristic that it can be diagnostic of pulmonary Langerhans cell histiocytosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58182 graphicRef69891 graphicRef72698 \" href=\"mobipreview.htm?16/61/17368\">",
"     image 3A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/35\">",
"     35",
"    </a>",
"    ]. The nodules can be poorly or well defined, but occasionally they can be large and bizarrely shaped. Honeycombing can be seen in advanced disease. The degree of cyst formation is often under appreciated by routine chest radiography. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=see_link&amp;anchor=H28#H28\">",
"     \"High resolution computed tomography of the lungs\", section on 'Langerhans cell histiocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serial chest CT scanning suggests a sequence of progression from nodules to cavitating nodules to cystic lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. This progression may explain a number of \"spontaneous remissions\" reported before the routine use of HRCT. The value of serial lung CT scanning in the routine follow-up of patients has been questioned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Fluorodeoxyglucose-PET scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluorodeoxyglucose-PET (FDG-PET) scans may show increased uptake in patients with PLCH, particularly when obtained early in the course of disease. This was evaluated in a series of 11 patients with PLCH, five of whom had abnormal FDG uptake in the lungs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/41\">",
"     41",
"    </a>",
"    ]. The patients with FDG-PET positivity were more likely to have nodular radiographic pattern, suggesting earlier disease; those with negative FDG-PET scans were more likely to have a cystic pattern and fewer nodules, suggesting later disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physiologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, total lung capacity and expiratory flow rates are well-preserved in pulmonary Langerhans cell histiocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/8,23,42-44\">",
"     8,23,42-44",
"    </a>",
"    ]. Predominantly nodular disease is usually associated with normal or restrictive pulmonary function tests, whereas cystic disease is more likely to be associated with abnormal physiologic testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/39\">",
"     39",
"    </a>",
"    ]. The following abnormalities can be seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diffusing capacity is disproportionately reduced in most patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subgroup of patients shows predominantly restrictive disease, with reduced total lung volume and increased elastic recoil.",
"     </li>",
"     <li>",
"      Airflow limitation and hyperinflation occur in a minority of patients, typically in patients with more advanced, cystic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. Airflow limitation is sometimes associated with reactive airways and significant improvement after bronchodilator administration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/6,23,37,43\">",
"       6,23,37,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Measurement of arterial blood gases in the patient at rest usually shows a normal alveolar-arterial oxygen difference and a normal PaCO",
"      <sub>",
"       2",
"      </sub>",
"      and pH. Thus, resting arterial blood gases are an insensitive indicator of disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Exercise physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pulmonary Langerhans cell histiocytosis generally demonstrate a limitation in activity and exercise intolerance out of proportion to pulmonary function abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/23\">",
"     23",
"    </a>",
"    ]. Markedly decreased exercise capacity, as measured by either work achieved or oxygen utilization (VO",
"    <sub>",
"     2",
"    </sub>",
"    ) at maximal exercise, is commonly present. The oxygen pulse at maximal exercise and at anaerobic threshold is reduced in most patients. The maximal ventilatory response is excessive (but not limiting) for the maximal level of work.",
"   </p>",
"   <p>",
"    Gas exchange abnormalities, reflected by a rising alveolar-arterial oxygen difference with increasing exercise, are seen in the majority of patients. In most patients, dead space to tidal volume ratio",
"    <span class=\"nowrap\">",
"     (VD/VT)",
"    </span>",
"    is either abnormally elevated at rest or fails to decrease with exercise. This abnormality suggests either pathologic or functional involvement of the pulmonary vasculature by the disease process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The finding of more than 5 percent Langerhans cells (CD-1a positive) on bronchoalveolar lavage (BAL) strongly suggests the diagnosis of pulmonary Langerhans cell histiocytosis (PLCH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/1,5,45,46\">",
"     1,5,45,46",
"    </a>",
"    ], but quantitative criteria for the diagnosis have not been conclusively established. A finding of less than 5 percent CD-1a positive cells does not exclude the diagnosis of PLCH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lower proportions of Langerhans cells can be seen in other settings (current smokers, patients with other interstitial lung disorders, bronchioloalveolar carcinoma). Therefore, the mere presence of Langerhans cells on BAL is of little diagnostic value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tissue confirmation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When tissue confirmation of the diagnosis is sought, transbronchial biopsy can be sufficient to make the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/47\">",
"     47",
"    </a>",
"    ]. However, a substantial number of false negative or nondiagnostic biopsies result from sampling error and insufficient tissue. Video thoracoscopic lung biopsy, on the other hand, is generally definitive. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Langerhans cells can be recognized by their characteristic staining for S-100 protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. These cells are also OKT-6 (CD1a) positive and demonstrate staining with the monoclonal antibody MT-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/50\">",
"     50",
"    </a>",
"    ]. Tissue immunostaining with the monoclonal antibody OKT-6 (CD1a) distinguishes Langerhans cells from other histiocytes, and can be a useful adjunct in difficult cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/51\">",
"     51",
"    </a>",
"    ]. Immunostaining can be performed on routinely fixed tissue and is less expensive than electron microscopy.",
"   </p>",
"   <p>",
"    In cases of progressive disease with extensive fibrosis, the number of Langerhans cells in either tissue specimens or bronchoalveolar lavage fluid decreases dramatically. Diagnosis at this stage can be difficult regardless of the laboratory methods used. In most cases, the combination of transbronchial lung biopsy and BAL supplemented with the identification of CD-1a positive cells in tissue and BAL fluid is highly likely to result in the correct diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/12,52\">",
"     12,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial focus of any therapeutic regimen in patients with pulmonary Langerhans cell histiocytosis is cessation of smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunosuppressive therapies, such as glucocorticoids and cytotoxic agents, are of",
"    <strong>",
"     limited",
"    </strong>",
"    value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/37,54,55\">",
"     37,54,55",
"    </a>",
"    ]. Unfortunately, no studies comparing different treatments in adults with lung disease have been performed. In our experience, only patients with prominent nodular opacities respond to glucocorticoid therapy. Case reports have described improvement in PLCH following treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    (2-chlorodeoxyadenosine), a chemotherapeutic agent cytotoxic for lymphocyte and monocyte cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The use of cladribine to treat Langerhans cell histiocytosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/45/28378?source=see_link&amp;anchor=H6873611#H6873611\">",
"     \"Treatment of Langerhans cell histiocytosis\", section on 'Relapsed or refractory disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation therapy for symptomatic bone lesions can be palliative, but it is not useful in treatment of the pulmonary manifestations.",
"   </p>",
"   <p>",
"    The efficacy of treatment of pulmonary hypertension complicating PLCH was examined in a series of 12 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/58\">",
"     58",
"    </a>",
"    ]. Therapy with an endothelin receptor antagonist, a phosphodiesterase 5 inhibitor,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    , or a combination led to modest improvements in mean pulmonary arterial pressure (from 56 &plusmn; 14 to 45 &plusmn; 12 mm Hg) and pulmonary vascular resistance (from 701 &plusmn; 239 to 469 &plusmn; 210 dynes-sec-cm",
"    <sup>",
"     -5",
"    </sup>",
"    ) between baseline and follow up evaluations. No significant worsening of oxygenation was observed with treatment.",
"   </p>",
"   <p>",
"    Lung transplantation should be considered in patients with advanced, progressive disease unless contraindications are present. Recurrence of the condition in the transplanted lung may occur, but it is unclear if this affects overall posttransplant survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical trials of therapy for LCH are ongoing, and enrollment may be appropriate for selected patients. In the United States, the Histiocyte Society initiated a series of protocols for treatment of adults with LCH in 2001. Treatment protocols and other information can be obtained through the Histiocytosis Association of America (1-800-548-2758 or",
"    <a class=\"external\" href=\"file://www.histio.org/\">",
"     www.histio.org",
"    </a>",
"    ) and at",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"     file://clinicaltrials.gov/",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of pulmonary Langerhans cell histiocytosis is variable, with some patients experiencing spontaneous remission of symptoms and others progressing to end-stage fibrotic lung disease (",
"    <a class=\"graphic graphic_figure graphicRef71979 \" href=\"mobipreview.htm?6/38/6765\">",
"     figure 3",
"    </a>",
"    ). Both smoking status and the radiographic picture can affect disease progression. Most subjects demonstrate gradual progression with continued cigarette smoking, while the disease may regress with the cessation of smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/53\">",
"     53",
"    </a>",
"    ]. Patients with radiographic sparing of the costophrenic angle are more likely to remain stable or improve compared to those with costophrenic angle involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/36\">",
"     36",
"    </a>",
"    ]. Pulmonary hypertension is common, and is independently associated with decreased survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a review of clinical outcomes drawn from the collected Mayo Clinic experience of 102 adult patients with pulmonary LCH, median survival (12.5 years from diagnosis) was shorter than for age-matched controls in the general population (",
"    <a class=\"graphic graphic_figure graphicRef72679 \" href=\"mobipreview.htm?25/4/25677\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/20\">",
"     20",
"    </a>",
"    ]. Estimated five and ten-year survival rates were 74 and 64 percent, respectively. Nearly half (15 of 33) of the deaths that occurred during the follow-up period were attributed to respiratory failure. The other major cause of death was malignancy, primarily of hematologic or epithelial origin.",
"   </p>",
"   <p>",
"    In a separate study of 29 patients with PLCH and pulmonary arterial hypertension, the one, three, and five-year survival estimates were 96, 92, and 73 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Follow-up testing every three months in the first year after diagnosis may be useful in identifying patients who are likely to develop progressive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35592/abstract/3,20\">",
"     3,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary Langerhans cell histiocytosis (PLCH) is an uncommon interstitial lung disease that primarily affects young adults. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The near universal association of PLCH with cigarette smoking strongly implies a causative role. In contrast, there does",
"      <strong>",
"       not",
"      </strong>",
"      appear to be an association of smoking with extrapulmonary Langerhans cell histiocytosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Langerhans cell, a differentiated cell of the monocyte-macrophage line, is the pathologic cell type of pulmonary Langerhans cell histiocytosis. These cells are positive on immunostaining with the monoclonal antibody OKT-6 that recognizes CD1 antigen (CD1a). Histopathologic lesions frequently extend widely into the parenchyma of the lung surrounding the bronchovascular structures, producing the so-called",
"      <strong>",
"       stellate lesions",
"      </strong>",
"      that are characteristic of this disorder (",
"      <a class=\"graphic graphic_picture graphicRef52774 graphicRef71884 graphicRef51661 \" href=\"mobipreview.htm?40/54/41834\">",
"       picture 4A-C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients usually present following a spontaneous pneumothorax or with a nonproductive cough, dyspnea, or constitutional symptoms, especially fever or weight loss. Recurrent spontaneous pneumothorax occurs in 15 to 25 percent of patients. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients may also have extrapulmonary histiocytosis with diabetes insipidus or cystic bone lesions. Pulmonary hypertension appears to be common among patients with PLCH, even in the absence of overt symptoms of right heart failure. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A high resolution computed tomography (HRCT) scan of the chest showing a combination of multiple cysts and nodules, with a mid to upper zone predominance, and interstitial thickening in a young smoker is so characteristic that it can be diagnostic of pulmonary Langerhans cell histiocytosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58182 graphicRef69891 graphicRef72698 \" href=\"mobipreview.htm?16/61/17368\">",
"       image 3A-C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary function tests may be normal or may show reduced lung volumes and a reduced diffusing capacity. Airflow limitation and hyperinflation occur in a minority of patients, typically in patients with more advanced, cystic disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Physiologic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the radiographic pattern is nondiagnostic, the combination of transbronchial lung biopsy and bronchoalveolar lavage (BAL) showing an increase in the number of CD-1a positive cells strongly suggests PLCH, especially when more than 5 percent of BAL cells are CD1a positive. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Tissue confirmation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main focus of any therapeutic regimen in patients with pulmonary Langerhans cell histiocytosis is cessation of smoking. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal therapy for patients who do not improve with smoking cessation is not known. In our experience, only patients with prominent nodular opacities respond to glucocorticoid therapy. Radiation therapy is not useful in treatment of the pulmonary manifestations, although it can be palliative for symptomatic bone lesions. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Information about clinical trials for patients with PLCH can be obtained at",
"      <a class=\"external\" href=\"file://www.histio.org/\">",
"       www.histio.org",
"      </a>",
"      or",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"       file://clinicaltrials.gov",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/1\">",
"      Tazi A, Soler P, Hance AJ. Adult pulmonary Langerhans' cell histiocytosis. Thorax 2000; 55:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/2\">",
"      Vassallo R, Ryu JH, Colby TV, et al. Pulmonary Langerhans'-cell histiocytosis. N Engl J Med 2000; 342:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/3\">",
"      Vassallo R, Ryu JH. Pulmonary Langerhans' cell histiocytosis. Clin Chest Med 2004; 25:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/4\">",
"      Sundar KM, Gosselin MV, Chung HL, Cahill BC. Pulmonary Langerhans cell histiocytosis: emerging concepts in pathobiology, radiology, and clinical evolution of disease. Chest 2003; 123:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/5\">",
"      Tazi A. Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J 2006; 27:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/6\">",
"      Casolaro MA, Bernaudin JF, Saltini C, et al. Accumulation of Langerhans' cells on the epithelial surface of the lower respiratory tract in normal subjects in association with cigarette smoking. Am Rev Respir Dis 1988; 137:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/7\">",
"      Soler P, Moreau A, Basset F, Hance AJ. Cigarette smoking-induced changes in the number and differentiated state of pulmonary dendritic cells/Langerhans cells. Am Rev Respir Dis 1989; 139:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/8\">",
"      Basset F, Corrin B, Spencer H, et al. Pulmonary histiocytosis X. Am Rev Respir Dis 1978; 118:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/9\">",
"      Travis WD, Borok Z, Roum JH, et al. Pulmonary Langerhans cell granulomatosis (histiocytosis X). A clinicopathologic study of 48 cases. Am J Surg Pathol 1993; 17:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/10\">",
"      Vassallo R, Jensen EA, Colby TV, et al. The overlap between respiratory bronchiolitis and desquamative interstitial pneumonia in pulmonary Langerhans cell histiocytosis: high-resolution CT, histologic, and functional correlations. Chest 2003; 124:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/11\">",
"      Fukuda Y, Basset F, Soler P, et al. Intraluminal fibrosis and elastic fiber degradation lead to lung remodeling in pulmonary Langerhans cell granulomatosis (histiocytosis X). Am J Pathol 1990; 137:415.",
"     </a>",
"    </li>",
"    <li>",
"     Vassallo R, Limper AH. Pulmonary Langerhans cell histiocytosis. In: Interstitial Lung Disease, 4th ed, King TE Jr, Schwarz MI (Eds), B.C. Decker, Hamilton, ON, Canada 2003. p.838.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/13\">",
"      Rowden G. The Langerhans cell. Crit Rev Immunol 1981; 3:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/14\">",
"      King TE Jr, Schwarz MI, Dreisin RE, et al. Circulating immune complexes in pulmonary eosinophilic granuloma. Ann Intern Med 1979; 91:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/15\">",
"      Aguayo SM, King TE Jr, Waldron JA Jr, et al. Increased pulmonary neuroendocrine cells with bombesin-like immunoreactivity in adult patients with eosinophilic granuloma. J Clin Invest 1990; 86:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/16\">",
"      Aguayo SM, Kane MA, King TE Jr, et al. Increased levels of bombesin-like peptides in the lower respiratory tract of asymptomatic cigarette smokers. J Clin Invest 1989; 84:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/17\">",
"      Petronilho F, Roesler R, Schwartsmann G, Dal Pizzol F. Gastrin-releasing peptide receptor as a molecular target for inflammatory diseases. Inflamm Allergy Drug Targets 2007; 6:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/18\">",
"      Youkeles LH, Grizzanti JN, Liao Z, et al. Decreased tobacco-glycoprotein-induced lymphocyte proliferation in vitro in pulmonary eosinophilic granuloma. Am J Respir Crit Care Med 1995; 151:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/19\">",
"      Yousem SA, Colby TV, Chen YY, et al. Pulmonary Langerhans' cell histiocytosis: molecular analysis of clonality. Am J Surg Pathol 2001; 25:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/20\">",
"      Vassallo R, Ryu JH, Schroeder DR, et al. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med 2002; 346:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/21\">",
"      G&ouml;tz G, Fichter J. Langerhans'-cell histiocytosis in 58 adults. Eur J Med Res 2004; 9:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/22\">",
"      Marcy TW, Reynolds HY. Pulmonary histiocytosis X. Lung 1985; 163:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/23\">",
"      Crausman RS, Jennings CA, Tuder RM, et al. Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology. Am J Respir Crit Care Med 1996; 153:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/24\">",
"      Epler GR, Carrington CB, Gaensler EA. Crackles (rales) in the interstitial pulmonary diseases. Chest 1978; 73:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/25\">",
"      Mendez JL, Nadrous HF, Vassallo R, et al. Pneumothorax in pulmonary Langerhans cell histiocytosis. Chest 2004; 125:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/26\">",
"      Fartoukh M, Humbert M, Capron F, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000; 161:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/27\">",
"      Chaowalit N, Pellikka PA, Decker PA, et al. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. Mayo Clin Proc 2004; 79:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/28\">",
"      Knight RK. Haemoptysis in eosinophilic granuloma. Br J Dis Chest 1979; 73:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/29\">",
"      Lombard CM, Medeiros LJ, Colby TV. Pulmonary histiocytosis X and carcinoma. Arch Pathol Lab Med 1987; 111:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/30\">",
"      Sadoun D, Vaylet F, Valeyre D, et al. Bronchogenic carcinoma in patients with pulmonary histiocytosis X. Chest 1992; 101:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/31\">",
"      Tomashefski JF, Khiyami A, Kleinerman J. Neoplasms associated with pulmonary eosinophilic granuloma. Arch Pathol Lab Med 1991; 115:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/32\">",
"      Tsuji T, Nakamura S, Tanaka M. Pulmonary Langerhans cell histiocytosis associated with lingual carcinoma. Intern Med 2004; 43:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/33\">",
"      Coli A, Bigotti G, Ferrone S. Histiocytosis X arising in Hodgkin's disease: immunophenotypic characterization with a panel of monoclonal antibodies. Virchows Arch A Pathol Anat Histopathol 1991; 418:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/34\">",
"      Aguayo, SM, Schwarz, MI, Mortenson, RL. The role of the chest radiograph in the evaluation of disease severity and clinical course in eosinophilic granuloma. Am Rev Respir Dis 1990; 141:A61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/35\">",
"      Kulwiec EL, Lynch DA, Aguayo SM, et al. Imaging of pulmonary histiocytosis X. Radiographics 1992; 12:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/36\">",
"      Lacronique J, Roth C, Battesti JP, et al. Chest radiological features of pulmonary histiocytosis X: a report based on 50 adult cases. Thorax 1982; 37:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/37\">",
"      Sch&ouml;nfeld N, Frank W, Wenig S, et al. Clinical and radiologic features, lung function and therapeutic results in pulmonary histiocytosis X. Respiration 1993; 60:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/38\">",
"      Brauner MW, Grenier P, Tijani K, et al. Pulmonary Langerhans cell histiocytosis: evolution of lesions on CT scans. Radiology 1997; 204:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/39\">",
"      Canuet M, Kessler R, Jeung MY, et al. Correlation between high-resolution computed tomography findings and lung function in pulmonary Langerhans cell histiocytosis. Respiration 2007; 74:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/40\">",
"      Tazi A, Marc K, Dominique S, et al. Serial computed tomography and lung function testing in pulmonary Langerhans' cell histiocytosis. Eur Respir J 2012; 40:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/41\">",
"      Krajicek BJ, Ryu JH, Hartman TE, et al. Abnormal fluorodeoxyglucose PET in pulmonary Langerhans cell histiocytosis. Chest 2009; 135:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/42\">",
"      Chusid, EL. Pulmonary eosinophilic granuloma: aspects of pulmonary function. Mt Sinai J Med 1961; 33:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/43\">",
"      Friedman PJ, Liebow AA, Sokoloff J. Eosinophilic granuloma of lung. Clinical aspects of primary histiocytosis in the adult. Medicine (Baltimore) 1981; 60:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/44\">",
"      HOFFMAN L, COHN JE, GAENSLER EA. Respiratory abnormalities in eosinophilic granuloma of the lung. Longterm study of five cases. N Engl J Med 1962; 26:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/45\">",
"      Harari S, Comel A. Pulmonary Langerhans cell Histiocytosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/46\">",
"      Auerswald U, Barth J, Magnussen H. Value of CD-1-positive cells in bronchoalveolar lavage fluid for the diagnosis of pulmonary histiocytosis X. Lung 1991; 169:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/47\">",
"      Housini I, Tomashefski JF Jr, Cohen A, et al. Transbronchial biopsy in patients with pulmonary eosinophilic granuloma. Comparison with findings on open lung biopsy. Arch Pathol Lab Med 1994; 118:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/48\">",
"      Ornvold K, Ralfkiaer E, Carstensen H. Immunohistochemical study of the abnormal cells in Langerhans cell histiocytosis (histiocytosis x). Virchows Arch A Pathol Anat Histopathol 1990; 416:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/49\">",
"      Ye F, Huang SW, Dong HJ. Histiocytosis X. S-100 protein, peanut agglutinin, and transmission electron microscopy study. Am J Clin Pathol 1990; 94:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/50\">",
"      Kahn HJ, Thorner PS. Monoclonal antibody MT1: a marker for Langerhans cell histiocytosis. Pediatr Pathol 1990; 10:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/51\">",
"      Soler P, Chollet S, Jacque C, et al. Immunocytochemical characterization of pulmonary histiocytosis X cells in lung biopsies. Am J Pathol 1985; 118:439.",
"     </a>",
"    </li>",
"    <li>",
"     King TE Jr. Bronchoscopy in interstitial lung disease. In: Textbook of Bronchoscopy, Feinsilver SH, Fein AM (Eds), Williams &amp; Wilkins, Baltimore 1995. p.185.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/53\">",
"      Mogulkoc N, Veral A, Bishop PW, et al. Pulmonary Langerhans' cell histiocytosis: radiologic resolution following smoking cessation. Chest 1999; 115:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/54\">",
"      Tsele E, Thomas DM, Chu AC. Treatment of adult Langerhans cell histiocytosis with etoposide. J Am Acad Dermatol 1992; 27:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/55\">",
"      Ladisch S, Gadner H. Treatment of Langerhans cell histiocytosis--evolution and current approaches. Br J Cancer Suppl 1994; 23:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/56\">",
"      Lazor R, Etienne-Mastroianni B, Khouatra C, et al. Progressive diffuse pulmonary Langerhans cell histiocytosis improved by cladribine chemotherapy. Thorax 2009; 64:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/57\">",
"      Aerni MR, Aubry MC, Myers JL, Vassallo R. Complete remission of nodular pulmonary Langerhans cell histiocytosis lesions induced by 2-chlorodeoxyadenosine in a non-smoker. Respir Med 2008; 102:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/58\">",
"      Le Pavec J, Lorillon G, Ja&iuml;s X, et al. Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest 2012; 142:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/59\">",
"      Gabbay E, Dark JH, Ashcroft T, et al. Recurrence of Langerhans' cell granulomatosis following lung transplantation. Thorax 1998; 53:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35592/abstract/60\">",
"      Habib SB, Congleton J, Carr D, et al. Recurrence of recipient Langerhans' cell histiocytosis following bilateral lung transplantation. Thorax 1998; 53:323.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4334 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-558F5CFEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_48_35592=[""].join("\n");
var outline_f34_48_35592=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Role of cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Fluorodeoxyglucose-PET scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physiologic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Exercise physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tissue confirmation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4334\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4334|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?22/28/22980\" title=\"diagnostic image 1\">",
"      Langerhans histiocytosis PA I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/14/10469\" title=\"diagnostic image 2\">",
"      Langerhans histiocytosis PA II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/29/34271\" title=\"diagnostic image 3A\">",
"      Langerhans histiocytosis CT I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/51/2864\" title=\"diagnostic image 3B\">",
"      Langerhans histiocytosis CT II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/37/21074\" title=\"diagnostic image 3C\">",
"      Pulmonary histiocytosis X CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4334|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/9/27805\" title=\"figure 1\">",
"      Smoking in pulm histiocytosis X",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/34/18989\" title=\"figure 2\">",
"      Age pulmonary histiocytosis X",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/38/6765\" title=\"figure 3\">",
"      Course pulmonary histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/4/25677\" title=\"figure 4\">",
"      Survival pulmonary LCH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4334|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/32/2570\" title=\"picture 1\">",
"      Birbeck granules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/25/27029\" title=\"picture 2\">",
"      Histiocytosis X High power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/41/28308\" title=\"picture 3\">",
"      Early lesion in PHX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/42/31399\" title=\"picture 4A\">",
"      Pulmonary histiocytosis X Low",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/2/21543\" title=\"picture 4B\">",
"      Stellate lesions I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/24/33158\" title=\"picture 4C\">",
"      Stellate lesions II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5096?source=related_link\">",
"      Evaluation of diffuse lung disease by conventional chest radiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/39/32378?source=related_link\">",
"      Pathogenesis of idiopathic pulmonary fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34633?source=related_link\">",
"      Respiratory bronchiolitis-associated interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/45/28378?source=related_link\">",
"      Treatment of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_48_35593="Malignant peritoneal mesothelioma: Treatment";
var content_f34_48_35593=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Malignant peritoneal mesothelioma: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/48/35593/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/48/35593/contributors\">",
"     Hedy Lee Kindler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/48/35593/contributors\">",
"     H Richard Alexander, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/48/35593/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/48/35593/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/48/35593/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/48/35593/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/48/35593/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H135335340\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant peritoneal mesothelioma (MPM) is an aggressive neoplasm that arises from the lining mesothelial cells of the peritoneum and spreads extensively within the confines of the abdominal cavity. Morbidity and mortality are almost entirely due to disease progression within the peritoneum and not distant metastatic spread.",
"   </p>",
"   <p>",
"    This topic review will cover the treatment of MPM. The epidemiology, histology, clinical features, diagnosis, and staging of MPM, as well as the treatment of pleural, pericardial, and tunica vaginalis mesothelioma are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17754?source=see_link\">",
"     \"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7622?source=see_link\">",
"     \"Epidemiology of malignant mesothelioma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/50/32552?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28312?source=see_link\">",
"     \"Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42329?source=see_link\">",
"     \"Systemic treatment for unresectable malignant pleural mesothelioma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135336267\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES AND PROGNOSTIC VARIABLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus as to the optimal treatment for MPM. Due to the rarity of this entity, most of the available clinical information about MPM treatment is derived from retrospective single-center series, which have inherent selection biases. Prospective clinical trials are few and small, and there are currently no randomized studies that compare one treatment to another. Much of the data on systemic chemotherapy in MPM are derived from pharmaceutical company Expanded Access Programs, which have more heterogeneous patient populations and less rigorous response assessment and toxicity reporting than a prospective clinical trial. Determinations about the activity of chemotherapeutic agents are often extrapolated from the more extensive data available from patients with pleural mesothelioma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42329?source=see_link\">",
"     \"Systemic treatment for unresectable malignant pleural mesothelioma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compounding the difficulty of interpreting data from select small series, MPM is quite heterogeneous in its clinical behavior (particularly between men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]). There are many prognostic variables, some of which are only evident at surgical evaluation. The different histologic types have different natural histories; the sarcomatoid subtype has a worse prognosis than the more common epithelial subtype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/3\">",
"     3",
"    </a>",
"    ] and there are two variants, both of which arise predominantly in women, that are associated with indolent clinical behavior. In general, the prognosis for peritoneal mesothelioma is slightly worse than for its pleural counterpart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17754?source=see_link&amp;anchor=H17#H17\">",
"     \"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\", section on 'Histology'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H135336351\">",
"     'Peritoneal mesothelioma variants'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following sections will focus on diffuse MPM, the most common type of clinical presentation. Management of the well-differentiated papillary and multicystic variants is described below. (See",
"    <a class=\"local\" href=\"#H135336351\">",
"     'Peritoneal mesothelioma variants'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the past, diffuse MPM was treated at most referral centers with a combination of systemic chemotherapy, palliative surgery, and sometimes, whole abdominal irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/5\">",
"     5",
"    </a>",
"    ]. Median survival was uniformly less than one year, and long-term survival was uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The median survival for untreated patients is approximately six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More recently, as experience with cytoreductive surgery and intraperitoneal chemotherapy has accumulated, particularly over the last five years, marked improvements in outcome have been reported compared to historical controls. Among centers with expertise in this form of therapy, reported median survival for appropriately selected patients approaches five years. For patients who are not candidates for this approach due to unresectable disease or medical comorbidities, systemic chemotherapy with contemporary",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    -based regimens achieves response rates comparable to those seen in patients with pleural mesothelioma and is now commonly incorporated into the treatment algorithm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135336274\">",
"    <span class=\"h1\">",
"     CYTOREDUCTIVE SURGERY AND INTRAPERITONEAL CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the last decade, aggressive regional therapy using cytoreduction surgery (CRS) and intraperitoneal chemotherapy has been increasingly applied to patients with peritoneal surface malignancies, including pseudomyxoma peritonei and malignant peritoneal mesothelioma (MPM). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=see_link&amp;anchor=H14#H14\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\", section on 'Aggressive cytoreduction and intraperitoneal chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rationale for this therapy in MPM is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MPM remains confined to the peritoneal cavity in the majority of cases. Because the peritoneal implants are superficial and do not invade the underlying tissues deeply until the late stages, the disease is amenable to complete or near complete cytoreduction in over one-half of all patients undergoing exploration. The completeness of surgical cytoreduction is a major prognostic factor (see below).",
"     </li>",
"     <li>",
"      Direct intraperitoneal administration of chemotherapy permits a several-fold increase in drug concentration in the peritoneum compared to systemic administration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/10\">",
"       10",
"      </a>",
"      ]. Despite this regional advantage, direct penetration into tumor tissue is limited to a few millimeters. This may be enhanced by heating the perfusate containing chemotherapy, but even so, this form of therapy is best restricted to small volume disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intraperitoneal chemotherapy used in the operating room with hyperthermia has many nomenclatures, including continuous hyperthermic peritoneal perfusion, heated intraoperative peritoneal chemotherapy, and hyperthermic intraperitoneal chemotherapy (HIPEC). The remainder of this topic review will use the term HIPEC. Some centers also extend the period of IP chemotherapy beyond the operating room, an approach termed early postoperative intraperitoneal chemotherapy (EPIC).",
"   </p>",
"   <p>",
"    Although randomized trials have not been conducted, as the number of centers utilizing this approach has expanded, significant improvements in outcome of MPM have been reported compared to historical controls. In several series, median survival approaches five years. (See",
"    <a class=\"local\" href=\"#H135336295\">",
"     'Results'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These results are achieved with optimally selected patient populations and with treatment delivery in a center with expertise in these technically demanding procedures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      This approach is best suited for patients with no evidence of extraperitoneal spread, a good performance status, and a disease burden that is amenable to complete cytoreduction to minimal residual disease (no deposits over 2 to 2.5 mm) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/11\">",
"       11",
"      </a>",
"      ]. It is unlikely that even a heated solution of chemotherapy could penetrate large tumor deposits.",
"     </li>",
"     <li>",
"      Patients with MPM should be managed at an institution with demonstrated experience in this therapy. The quality of the CRS is dependent upon the skills and level of experience of the surgeon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/12\">",
"       12",
"      </a>",
"      ]. Even at dedicated treatment centers, major morbidity is experienced by at least 30 percent of patients, the median hospital stay is 12 days, and the operative mortality rate is about 2 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The favorable results (particularly with regard to treatment-related toxicity) achieved by international experts in the field may not be replicated in routine clinical practice. Guidance as to centers with expertise in treatment of peritoneal mesothelioma is available from the nonprofit",
"    <a class=\"external\" href=\"file://www.curemeso.org/site/c.kkLUJ7MPKtH/b.3076109/k.FF9C/Mesothelioma_Applied_Research_Foundation.htm\">",
"     Mesothelioma Applied Research Foundation (MARF)",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135336281\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors are associated with better outcomes after CRS and HIPEC, some of which are useful for stratifying patients into groups that are more or less likely to benefit from this aggressive approach. These include disease extent and depth of tumor invasion beyond the mesothelial surface, completeness of cytoreduction, histology (epithelioid better than sarcomatoid), age (less than 60 better than older), and weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. Female gender may also be independently associated with a better prognosis, with younger women (&lt;55 years of age) doing better than older women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/19\">",
"     19",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Results from the initial staging CT scan can be used to predict the likelihood of complete surgical cytoreduction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17754?source=see_link&amp;anchor=H11#H11\">",
"     \"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\", section on 'Radiographic imaging'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Sugarbaker's group at the Washington Hospital Center systematically scored findings on preoperative CT scans from 30 patients undergoing CRS and HIPEC for MPM, and identified features associated with adequacy of cytoreduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/20\">",
"     20",
"    </a>",
"    ]. The presence of a &gt;5 cm mass in the epigastric region and loss of normal architecture of the small bowel and its mesentery (matted adjacent small bowel loops, distorted and thickened configuration, segmental small bowel obstruction, small bowel mesenteric vessels difficult to define due to obliteration of mesenteric fat) were the radiographic features that were most strongly associated with suboptimal cytoreduction. Patients who had neither of these two findings had a 94 percent probability of adequate cytoreduction (defined as all residual tumor nodules &lt;2.5 cm in diameter), while no patient with both findings had a successful surgical cytoreduction.",
"   </p>",
"   <p>",
"    Radiographic criteria such as these are one of the selection factors used by Sugarbaker and other groups to select patients with a peritoneal surface malignancy who are most likely to benefit from aggressive surgical debulking and HIPEC. His group uses four preoperative and intraoperative features to select patients for combined treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preoperative contrast (oral and IV)-enhanced CT of the chest, abdomen and pelvis &ndash; In addition to excluding liver or other systemic metastases, the finding of segmental obstruction of the small bowel and tumor nodules &gt;5 cm in diameter on small bowel surfaces or directly adjacent to the small bowel mesentery in the jejunum or upper ileum predict a poor outcome from CRS and HIPEC.",
"     </li>",
"     <li>",
"      Histopathology &ndash; Noninvasive malignancies such as mesothelioma are more likely to be made visibly disease-free through a peritonectomy procedure and are less likely that other invasive histologies (eg, colonic adenocarcinoma) to have spread to regional nodes, liver, or other systemic sites.",
"     </li>",
"     <li>",
"      Two other clinical indices, the peritoneal cancer index (PCI, a quantitative prognostic indicator derived from the size and distribution of peritoneal surface nodules) and the completeness of cytoreduction score (ie, size of persisting nodules after maximal cytoreduction) are derived intraoperatively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laparoscopy may also be used to predict which patients are likely to have a complete surgical cytoreduction during a subsequent laparotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135336288\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative procedures that may be used to achieve complete gross cytoreduction include omentectomy, splenectomy, small and large bowel resection, peritonectomy, hysterectomy, salpingectomy, oophorectomy, and low anterior resection. Implants on the serosa of the small bowel, capsule of the liver, or other solid viscera are usually treated by electrical or argon beam coagulation or some other type of electrofulguration.",
"   </p>",
"   <p>",
"    HIPEC is done selectively and may be omitted if CRS has been suboptimal. The degree to which surgical cytoreduction versus intraperitoneal chemotherapy contributes to patient outcomes is unclear. The treatment parameters for HIPEC (type of chemotherapy, degree of hyperthermia, and duration of perfusion) vary considerably from one institution to another (",
"    <a class=\"graphic graphic_table graphicRef76769 \" href=\"mobipreview.htm?5/48/5899\">",
"     table 1",
"    </a>",
"    ), and there are almost no data to support any specific regimen over another. Some observational data suggest that patients treated with intraperitoneal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    may have superior survival compared to those treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    ; however, interpretation of this analysis is limited by its retrospective nature and the small number of patients (n=34) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/24\">",
"     24",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Our approach at the University of Maryland includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After maximal surgical debulking, large bore catheters are placed within the peritoneal cavity and connected to an extracorporeal recirculating perfusion circuit consisting of a reservoir, roller pump, and heat exchanger.",
"     </li>",
"     <li>",
"      4 to 6 L of perfusate containing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      C at a dose of 40 mg are circulated through the peritoneal cavity for 90 minutes. The perfusate is warmed to achieve target intraperitoneal temperatures between 40 and 42&ordm;C.",
"     </li>",
"     <li>",
"      We do not typically leave catheters in place for postoperative continuation of IP chemotherapy but others do [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/14,25,26\">",
"       14,25,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135336295\">",
"    <span class=\"h2\">",
"     Results",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of centers in the US and Europe have published phase II or observational experience with cytoreduction surgery (CRS) and HIPEC for MPM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/14,16,17,26-37\">",
"     14,16,17,26-37",
"    </a>",
"    ]. Treatment protocols vary among institutions, with some using HIPEC alone and others HIPEC in conjunction with EPIC. All studies, however, share two of the most important therapeutic concepts in this disease: maximal CRS to remove macroscopic disease and intraperitoneal chemotherapy delivered immediately after CRS to eradicate residual tumor cells.",
"   </p>",
"   <p>",
"    Results from several expert centers and a multi-institutional series are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef64317 \" href=\"mobipreview.htm?43/40/44685\">",
"     table 2",
"    </a>",
"    ). The techniques and range of findings from three groups and a multicenter international registry study are described in detail below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Washington Hospital Center &ndash; Sugarbaker and colleagues have made many important contributions to the management of patients with peritoneal surface malignancies, including MPM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/17,25,35,38\">",
"       17,25,35,38",
"      </a>",
"      ]. The most recent report detailed 70 consecutive patients treated by the same surgical team with CRS, HIPEC, and early postoperative IP chemotherapy (EPIC) for MPM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/25\">",
"       25",
"      </a>",
"      ]. HIPEC consisted of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      delivered under hyperthermic conditions for 90 minutes in the operating room. Closed suction drains remained in place in all patients postoperatively, one beneath the right hemidiaphragm, another beneath the left hemidiaphragm, and two in the pelvis. During postoperative days 1 to 5, 46 patients received IP",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day in 1 L of 1.5 percent dextrose peritoneal dialysis solution or 6 percent hydroxyethyl starch (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/13/9430?source=see_link\">",
"       hetastarch",
"      </a>",
"      ) solution, with a dwell time of 23 hours, and a turn in patient position every 30 minutes for the first six hours. EPIC was withheld in 24 patients because of postoperative bleeding, respiratory instability or another severe postoperative complication, low white blood cell (WBC) count related to prior chemotherapy, or chemotherapy agent not available (n=9).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       Filgrastim",
"      </a>",
"      was started empirically in the postoperative period if the total WBC count dropped below",
"      <span class=\"nowrap\">",
"       2000/microL.",
"      </span>",
"      Following treatment, all patients were monitored with CT scans every six months.",
"      <br/>",
"      <br/>",
"      The mean age was 48, reflecting the young, otherwise healthy, highly selected patient population. Mean operative duration was eight hours, and the mean length of hospital stay was 23 days. There were two perioperative deaths. Treatment-related toxicity requiring invasive intervention developed in 41 percent of patients. At median follow-up of 35 months, the one-, three-, and five-year survival rates were 82, 57, and 49 percent, respectively.",
"      <br/>",
"      <br/>",
"      Prognostic factors were addressed in a separate report of 62 patients undergoing CRS and IP chemotherapy for diffuse MPM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/17\">",
"       17",
"      </a>",
"      ]. Although several factors were significant in the univariate analysis (completeness of cytoreduction, cell type, mitotic count, radiographic findings on preoperative CT, and gender), the only factor that was independently associated with survival in multivariate analysis was mesothelioma nuclear size.",
"     </li>",
"     <li>",
"      NCI Bethesda &ndash; The most favorable long-term outcomes were reported by the National Cancer Institute (NCI) from a phase II study of 49 patients with MPM treated with CRS and HIPEC (heated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      for 90 minutes) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/14\">",
"       14",
"      </a>",
"      ]. Although several factors were significant in the univariate analysis (completeness of cytoreduction, cell type, mitotic count, radiographic findings on preoperative CT, and gender), the only factor that was independently associated with survival in multivariate analysis was mesothelioma",
"      <span class=\"nowrap\">",
"       nuclear/nucleolar",
"      </span>",
"      size.",
"      <br/>",
"      <br/>",
"      The median progression-free and overall survival durations were 17 and 92 months, respectively, and the one- and three-year survival rates were 86 and 59 percent, respectively (",
"      <a class=\"graphic graphic_figure graphicRef58303 \" href=\"mobipreview.htm?0/53/862\">",
"       figure 1",
"      </a>",
"      ). However, 36 percent of the patients in this series had low-grade histology that was described as \"adenomatoid\" or tubulopapillary, most of which had no evidence of deep tissue invasion. Nevertheless, in contrast to the findings of others, histology was not associated with outcomes in multivariate analysis.",
"     </li>",
"     <li>",
"      Columbia-Presbyterian &ndash; These investigators have employed an aggressive multimodality two-staged approach for patients with MPM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/16,32\">",
"       16,32",
"      </a>",
"      ]. In a phase II trial, 27 patients had initial surgical debulking and placement of an IP catheter, followed by IP",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and gamma interferon for four months. Subsequently, a second laparotomy was performed with attempted complete cytoreduction of residual disease and HIPEC using cisplatin and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      C followed by whole abdominal radiotherapy (RT). RT was not received by 13 patients because of the finding of unresectable disease, a complication precluding RT, or patient refusal.",
"      <br/>",
"      <br/>",
"      Treatment was remarkably well tolerated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/16\">",
"       16",
"      </a>",
"      ]. Grade 3 or 4 toxicities included small bowel obstruction, fistula, chemical peritonitis, and catheter infection in one patient each, and ototoxicity in two patients. There were no perioperative deaths. The median overall survival was 70 months, with a three-year survival of 67 percent.",
"     </li>",
"     <li>",
"      International registry study &ndash; Another series reported results on 401 patients with MPM who were treated with cytoreductive surgery without (n=29) or with (n=311) HIPEC (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ) between 1999 and 2009 at one of eight institutions in the US, Europe, or Australia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/27\">",
"       27",
"      </a>",
"      ]. The mean duration of surgery was eight hours, and 188 (46 percent) of patients had complications, considered severe in 127. Operative mortality was 2 percent. Three- and five-year survival rates were 60 and 47 percent, respectively. There were four factors that were independently associated with survival: epithelioid histology, absence of nodal metastases, complete or near-complete cytoreduction, and the use of HIPEC. However, because the decision to use HIPEC was made individually for each patient, the association between HIPEC and survival must be interpreted cautiously.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135336302\">",
"    <span class=\"h2\">",
"     Treatment-related toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In expert hands, CRS and HIPEC treatment is associated with an operative mortality rate that ranges from 0 to 8 percent, and rates of serious perioperative morbidity are between 10 and 45 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/14,16,17,26-37\">",
"     14,16,17,26-37",
"    </a>",
"    ]. Complications related to chemotherapy are almost invariably related to myelosuppression, while complications related to laparotomy and CRS include fistula, bleeding, wound infection, and sepsis.",
"   </p>",
"   <p>",
"    In the NCI series of 48 patients described above, the most frequent perioperative complications were wound infection, fascial dehiscence, pleural effusion, prolonged ileus, and catheter sepsis (6, 4, 4, 4, and 4 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/14\">",
"     14",
"    </a>",
"    ]. Additional complications with a lower incidence include enterocutaneous fistula, small bowel obstruction, pneumothorax, prolonged mechanical ventilation, acute renal failure, hematologic toxicity, pancreatitis, and abdominal wall herniation.",
"   </p>",
"   <p>",
"    In a report from the Sugarbaker group, treatment-related toxicity was categorized as grade 1, no intervention reported for resolution; grade 2, medical treatment sufficient for resolution; grade 3, in invasive (eg, radiologic or transfusional) intervention required for resolution; grade 4, urgent definitive intervention (eg, return to the operating room or to the surgical intensive care unit) required for resolution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/25\">",
"     25",
"    </a>",
"    ]. Grade 3 or 4 morbidity rates were 27 and 14 percent, respectively. Low hemoglobin level was responsible for 26 percent of all grade 3 toxicities, while central line sepsis and urinary tract infection accounted for 17 and 13 percent, respectively. Postoperative bleeding requiring a return to the operative room accounted for 38 percent of the grade 4 adverse events, and respiratory failure requiring intubation was responsible for 22 percent. Risk factors for grade 4 morbidity included primary colonic anastomosis, more than four peritonectomy procedures, and operative duration over seven hours.",
"   </p>",
"   <p>",
"    These data are derived from groups with demonstrated experience and expertise in the procedure, and they may not be replicated in routine clinical practice. Guidance as to centers with expertise in treatment of peritoneal mesothelioma is available from the nonprofit",
"    <a class=\"external\" href=\"file://www.curemeso.org/site/c.kkLUJ7MPKtH/b.3076109/k.FF9C/Mesothelioma_Applied_Research_Foundation.htm\">",
"     Mesothelioma Applied Research Foundation (MARF).",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135336309\">",
"    <span class=\"h1\">",
"     SYSTEMIC CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytotoxic chemotherapy is an option for patients who are not candidates for CRS and HIPEC, due to unresectable disease or medical comorbidities. The role of systemic chemotherapy in a multi-modality setting (adjuvant or neoadjuvant) has not been formally addressed in clinical trials or case series in this disease.",
"   </p>",
"   <p>",
"    Most clinical trials that evaluate new drugs or drug combinations in mesothelioma specifically exclude patients with peritoneal mesothelioma. Thus, assumptions about the activity of various chemotherapeutic agents for peritoneal mesothelioma are often extrapolated from the more extensive data derived from patients with pleural mesothelioma. Those trials that do permit the enrollment of other mesothelioma disease sites generally include few peritoneal mesothelioma subjects, due to the rarity of peritoneal mesothelioma and the standard eligibility requirement for radiologically measurable disease, which can be difficult to determine in the peritoneal cavity. Trials that have been conducted exclusively in patients with peritoneal mesothelioma are quite uncommon. Despite variations in gene expression profiles that suggest different pathophysiology for pleural and peritoneal mesothelioma, it is generally assumed (and supported by uncontrolled data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/39\">",
"     39",
"    </a>",
"    ]) that the efficacy of most systemic chemotherapy is similar in both disease sites.",
"   </p>",
"   <p>",
"    A meta-analysis of clinical trials reported between 1965 and 2001 determined that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    was the single most active cytotoxic agent against mesothelioma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/40\">",
"     40",
"    </a>",
"    ]. Single-agent cisplatin was used as the control arm of two large phase III trials in pleural mesothelioma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], although in clinical practice, it is never administered as monotherapy outside of a clinical trial setting. The addition of cisplatin to other active single agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/1/21525?source=see_link\">",
"     raltitrexed",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    , increases the objective response rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42329?source=see_link&amp;anchor=H6#H6\">",
"     \"Systemic treatment for unresectable malignant pleural mesothelioma\", section on 'Single agent chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The antifolates are currently considered the most active class of drugs against mesothelioma.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     Pemetrexed",
"    </a>",
"    , an antifolate that inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), is the first and only drug approved in the United States for the treatment of mesothelioma. Approval was based upon a single-blind, placebo-controlled, randomized phase III study in which 456 patients with pleural mesothelioma were randomly assigned to pemetrexed, 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every 21 days plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , 75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    or placebo with cisplatin. Those patients who received pemetrexed plus cisplatin achieved a significantly superior overall survival (12.1 versus 9.3 months, respectively; p = 0.020), longer time to disease progression (5.7 versus 3.9 months, p = 0.001), and higher objective response rate (41 versus 17 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42329?source=see_link&amp;anchor=H1937732994#H1937732994\">",
"     \"Systemic treatment for unresectable malignant pleural mesothelioma\", section on 'Pemetrexed plus cisplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following discussion will focus on data obtained in patients with malignant peritoneal mesothelioma (MPM). General principles of systemic therapy for pleural and other forms of mesothelioma are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42329?source=see_link\">",
"     \"Systemic treatment for unresectable malignant pleural mesothelioma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135336316\">",
"    <span class=\"h2\">",
"     Pemetrexed plus cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with MPM, the available data suggest that the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is comparable to that seen in pleural mesothelioma, and the regimen has generally been well tolerated. The utility of pemetrexed in patients with MPM has principally been demonstrated in analyses of the Pemetrexed Expanded Access Program, both in the US and internationally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Prospective phase II or III clinical trials of this regimen have not been conducted in patients with peritoneal mesothelioma, however.",
"   </p>",
"   <p>",
"    Of the 1056 mesothelioma patients enrolled in the US expanded access program prior to FDA approval of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    , 98 (9.3 percent) had peritoneal mesothelioma. Fifty-seven were previously-treated, and 38 were chemotherapy-naive. Patients received either pemetrexed alone (500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every 21 days, n = 32) or the same dose of pemetrexed in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every 21 days, n=66) for six cycles or until disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/8\">",
"     8",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    (350 to 600 micrograms daily) and vitamin B12 (1000 microgram intramuscularly one to two weeks before the first dose, then every nine weeks) were administered to all patients. Vitamin supplementation improves response to therapy and reduces treatment-related toxicity.",
"   </p>",
"   <p>",
"    Since measurable disease was not required for enrollment, only 73 patients with MPM were evaluable for response (28 chemotherapy-naive and 43 previously treated). Twenty-six received single-agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    and 47 were given the two-drug combination. There were 19 objective responses (four complete) for an overall response rate of 26 percent; another 45 percent had stable disease. The disease control rate (objective responses plus stable disease) was 71 percent, and similar objective response rates were achieved in the previously-treated and chemotherapy-naive patients. Median overall survival for previously treated patients was 13.1 months; it had not been reached at the time of the analysis for chemotherapy-naive patients. As expected, both response rate (29 versus 19 percent) and median survival (13.1 versus 8.7 months) were higher with the pemetrexed doublet than with pemetrexed alone (although the survival outcomes could easily reflect patient selection in this non-randomized study), and in both cases, the results were comparable to those seen in pleural mesothelioma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42329?source=see_link&amp;anchor=H1937732994#H1937732994\">",
"     \"Systemic treatment for unresectable malignant pleural mesothelioma\", section on 'Pemetrexed plus cisplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment appeared to be well-tolerated. The safety database of 1056 patients did not distinguish between patients with pleural or peritoneal mesothelioma, so it is uncertain whether there were any distinct toxicities in the peritoneal subset. The safety analysis in this trial relied on investigator reported serious adverse events, and thus the true rate of toxicity derived from analysis of experience in the Expanded Access Program is likely much greater than reported. Grade 3 or 4 hematologic toxicity (primarily anemia) was documented in only 2 percent of patients and neutropenia in less than 1 percent. The most common grade 3 or 4 non-hematologic toxicities were dehydration, nausea, and vomiting (7, 5, and 5 percent, respectively).",
"   </p>",
"   <p>",
"    Similar results were achieved in a preliminary report of a small observational series which has only been published in abstract form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/44\">",
"     44",
"    </a>",
"    ]. Of the 22 patients (15 chemotherapy-naive) who were treated at a single-center in Germany with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    and either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (21 patients) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    (area under the concentration x time curve [AUC] 5), the objective response rate was 36 percent and the overall disease control rate was 77 percent. Median time to progression was 11.5 months, and survival time was 13.7 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8238484\">",
"    <span class=\"h2\">",
"     Pemetrexed plus carboplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     Carboplatin",
"    </a>",
"    is often substituted for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , particularly in the palliative setting and in older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42329?source=see_link&amp;anchor=H1937733683#H1937733683\">",
"     \"Systemic treatment for unresectable malignant pleural mesothelioma\", section on 'Pemetrexed plus carboplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the International",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     Pemetrexed",
"    </a>",
"    Expanded Access Program, 29 evaluable patients with peritoneal mesothelioma received pemetrexed 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , dosed at an area under the concentration x time curve (AUC) of 5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/9\">",
"     9",
"    </a>",
"    ]. Seven patients (24 percent) had objective responses (one complete), and 52 percent had stable disease. These results are comparable those achieved with pemetrexed and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135336323\">",
"    <span class=\"h2\">",
"     Pemetrexed plus gemcitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the largest prospective multicenter chemotherapy experiences reported in peritoneal mesothelioma evaluated the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (1250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 and 8) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    (500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 8, before gemcitabine) in 20 chemotherapy-na&iuml;ve but highly selected patients with peritoneal mesothelioma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/45\">",
"     45",
"    </a>",
"    ]. A median of six cycles were delivered. There were three partial responses (response rate 15 percent), 35 percent had stable disease, for a disease control rate of 50 percent. Median time to disease progression was 10.4 months, and median overall survival was 26.8 months, and one-year survival was 67.5 percent. However, hematologic toxicity was substantial, and included grade 3 or 4 neutropenia in 60 percent, febrile neutropenia in 10 percent, and grade 4 anemia in 5 percent. The most common grade 3 and 4 non-hematologic toxicities included fatigue in 20 percent, and constipation, vomiting, and dehydration, each in 10 percent of patients.",
"   </p>",
"   <p>",
"    Importantly, this phase II trial was actually conducted in patients with pleural mesothelioma, and this report covered the 20 patients with peritoneal mesothelioma who were allowed to enroll, but without a statistical plan for separate analysis. As such, the data should be considered the equivalent of an observational study. We do not consider this a valid regimen for peritoneal mesothelioma given its toxicity and the low response rate (15 percent), which is comparable to that which can be achieved using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    alone, and lower than would be expected with pemetrexed plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135336337\">",
"    <span class=\"h2\">",
"     Cisplatin plus irinotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Responses have also been described with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    administered intraperitoneally or IV, in combination with IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    in a retrospective single-institution series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2354825404\">",
"    <span class=\"h2\">",
"     Other cytotoxic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     Gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    is an active regimen in pleural mesothelioma, but data are not available in peritoneal patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/43\">",
"     43",
"    </a>",
"    ]. Similarly,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    has a 24 percent single agent response rate in the front-line setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/47\">",
"     47",
"    </a>",
"    ] and a 16 percent response rate in previously-treated pleural mesothelioma patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/48\">",
"     48",
"    </a>",
"    ]. Whether these data are applicable to peritoneal patients is unclear, but the drugs are often used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135336344\">",
"    <span class=\"h2\">",
"     Molecularly targeted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preclinical data suggest a possible role for phosphatidylinositol-3-kinase and mammalian target of rapamycin",
"    <span class=\"nowrap\">",
"     (P13K/mTOR)",
"    </span>",
"    signaling pathways in the malignant phenotype of diffuse MPM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/49\">",
"     49",
"    </a>",
"    ]; phase I and II trials of agents that target these pathways are ongoing.",
"   </p>",
"   <p>",
"    The epidermal growth factor receptor (EGFR) is overexpressed in some pleural mesotheliomas; however, phase II trials of tyrosine kinase inhibitors that target the EGFR have been disappointing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42329?source=see_link&amp;anchor=H15#H15\">",
"     \"Systemic treatment for unresectable malignant pleural mesothelioma\", section on 'Molecularly targeted therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although activating EGFR mutations are rare in pleural mesothelioma, these occur in about 30 percent of peritoneal tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/50\">",
"     50",
"    </a>",
"    ]. An ongoing study at the University of Chicago is administering",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    to patients with peritoneal mesothelioma who have activating EGFR mutations. Data on agents that target novel molecular pathways in mesothelioma, including mesothelin, the EGFR, and vascular endothelial growth factor pathways, as well as inhibitors of histone deacetylase and FAK are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42329?source=see_link&amp;anchor=H15#H15\">",
"     \"Systemic treatment for unresectable malignant pleural mesothelioma\", section on 'Molecularly targeted therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135336351\">",
"    <span class=\"h1\">",
"     PERITONEAL MESOTHELIOMA VARIANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two rare variants of peritoneal mesothelioma. Both are characterized by indolent behavior and the potential for malignant transformation to MPM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135336358\">",
"    <span class=\"h2\">",
"     Well-differentiated papillary mesothelioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Well-differentiated papillary mesothelioma is a rare clinicopathologic entity that is distinct from MPM. It occurs predominantly in women of reproductive age and most often arises from the peritoneal surfaces of the pelvis. It is typically identified as an incidental finding at surgery performed for another indication, and there is no reported association with asbestos exposure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17754?source=see_link&amp;anchor=H8237767#H8237767\">",
"     \"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\", section on 'Well-differentiated papillary mesothelioma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Well-differentiated papillary mesothelioma is generally considered a low-grade malignancy, with a high rate of cure following complete surgical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Long-term follow-up is required because of the potential to progress to true MPM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Extensive debulking surgery and HIPEC are not warranted initially because of the indolent nature of the disease, but could be considered for patients with recurrent or more extensive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135336365\">",
"    <span class=\"h2\">",
"     Multicystic mesothelioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multicystic mesothelioma (also termed benign cystic mesothelioma, peritoneal inclusion cyst) is an unusual cystic tumor that most commonly arises from the pelvic peritoneal surfaces in young and middle-aged women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]. Men represent only 17 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/57\">",
"     57",
"    </a>",
"    ]. The majority of cases present with chronic or intermittent lower abdominal or pelvic pain, but occasionally, the diagnosis is made incidentally at surgery or on cross-sectional imaging. There is no association with asbestos exposure.",
"   </p>",
"   <p>",
"    Although the disease is well characterized histologically, the pathogenesis (in particular whether it represents a reactive mesothelial proliferation or a true neoplasm), natural history, and clinical management are not well defined. The clinical course is usually indolent, and surgical resection can be curative. However, long-term follow-up is needed, since local recurrence can occur in up to 50 percent from 1 to 27 years after initial diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/56\">",
"     56",
"    </a>",
"    ], and malignant transformation is reported.",
"   </p>",
"   <p>",
"    Surgical cytoreduction and HIPEC has been associated with long-term progression-free survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/48/35593/abstract/54,59\">",
"     54,59",
"    </a>",
"    ] and may be best applied when there is evidence of progression after initial resection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17754?source=see_link&amp;anchor=H8237774#H8237774\">",
"     \"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\", section on 'Multicystic mesothelioma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135336372\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignant peritoneal mesothelioma (MPM) is an aggressive neoplasm that arises from the lining mesothelial cells of the peritoneum. As with mesothelioma arising in other sites, there is a strong relationship between asbestos exposure and the development of MPM, particularly in men. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17754?source=see_link&amp;anchor=H2#H2\">",
"       \"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\", section on 'Epidemiology and risk factors'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The majority of cases of MPM present with diffuse peritoneal involvement (diffuse MPM). Morbidity and mortality are almost entirely due to disease progression within the peritoneum and not distant metastatic spread. Because the peritoneal implants are superficial and do not invade the underlying tissues deeply until the late stages, the disease is amenable to complete or near complete cytoreduction in over one-half of all patients undergoing exploration. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17754?source=see_link&amp;anchor=H7#H7\">",
"       \"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\", section on 'Clinical presentation and imaging features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For selected patients with diffuse MPM, no extraperitoneal disease spread, a good performance status, and who can be predicted to achieve complete surgical cytoreduction, we recommend regional therapy using cytoreduction surgery (CRS) and hyperthermic intraoperative peritoneal perfusion with chemotherapy (HIPEC) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). At our institution, we use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H135336274\">",
"       'Cytoreductive surgery and intraperitoneal chemotherapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Although randomized trials have not been conducted, as the number of centers utilizing this approach has expanded, particularly over the last five years, marked improvements in outcome have been reported compared to historical controls. Among centers with expertise in this form of therapy, reported median survival approaches five years. Referral of these patients to a center with expertise in the management of MPM is preferred. (See",
"      <a class=\"local\" href=\"#H135336295\">",
"       'Results'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cytotoxic chemotherapy is a reasonable option for patients who are not candidates for cytoreductive surgery and HIPEC. We suggest a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      -containing regimen over other chemotherapy options (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Pemetrexed plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      is an active regimen if the patient's performance status and general health are adequate to tolerate it. Particularly in the palliative setting, pemetrexed plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      is a very reasonable option that achieves similar results with less toxicity. (See",
"      <a class=\"local\" href=\"#H135336316\">",
"       'Pemetrexed plus cisplatin'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      When the chemotherapy regimen includes pemetrexed, concurrent supplementation with vitamin B12 and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      is needed to reduce toxicity. (See",
"      <a class=\"local\" href=\"#H135336316\">",
"       'Pemetrexed plus cisplatin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest initial surgical resection alone rather than CRS and HIPEC for patients with the indolent well-differentiated peritoneal mesothelioma and multicystic mesothelioma variants (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Long-term follow-up is warranted. (See",
"      <a class=\"local\" href=\"#H135336351\">",
"       'Peritoneal mesothelioma variants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the more aggressive nature and worse outcome of this disease in men, it is a reasonable approach to first try systemic therapy upfront in some male patients, and only offer CRS with HIPEC to those who respond.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/1\">",
"      Kerrigan SA, Turnnir RT, Clement PB, et al. Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients. Cancer 2002; 94:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/2\">",
"      Eltabbakh GH, Piver MS, Hempling RE, et al. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999; 70:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/3\">",
"      Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 2003; 12:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/4\">",
"      van der Bij S, Koffijberg H, Burgers JA, et al. Prognosis and prognostic factors of patients with mesothelioma: a population-based study. Br J Cancer 2012; 107:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/5\">",
"      Antman KH, Pomfret EA, Aisner J, et al. Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol 1983; 1:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/6\">",
"      Chailleux E, Dabouis G, Pioche D, et al. Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest 1988; 93:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/7\">",
"      Yates DH, Corrin B, Stidolph PN, Browne K. Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax 1997; 52:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/8\">",
"      J&auml;nne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 2005; 7:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/9\">",
"      Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 2009; 64:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/10\">",
"      Ceelen WP, P&aring;hlman L, Mahteme H. Pharmacodynamic aspects of intraperitoneal cytotoxic therapy. Cancer Treat Res 2007; 134:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/11\">",
"      Deraco M, Bartlett D, Kusamura S, Baratti D. Consensus statement on peritoneal mesothelioma. J Surg Oncol 2008; 98:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/12\">",
"      Yan TD, Links M, Fransi S, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy--a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol 2007; 14:2270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/13\">",
"      Gusani NJ, Cho SW, Colovos C, et al. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol 2008; 15:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/14\">",
"      Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003; 21:4560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/15\">",
"      Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori 2003; 89:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/16\">",
"      Hesdorffer ME, Chabot JA, Keohan ML, et al. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol 2008; 31:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/17\">",
"      Yan TD, Brun EA, Cerruto CA, et al. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2007; 14:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/18\">",
"      Yan TD, Popa E, Brun EA, et al. Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg 2006; 93:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/19\">",
"      Cao C, Yan TD, Deraco M, et al. Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol 2012; 23:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/20\">",
"      Yan TD, Haveric N, Carmignani CP, et al. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 2005; 103:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/21\">",
"      Sugarbaker PH. Managing the peritoneal surface component of gastrointestinal cancer. Part 1. Patterns of dissemination and treatment options. Oncology (Williston Park) 2004; 18:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/22\">",
"      Sugarbaker PH. Managing the peritoneal surface component of gastrointestinal cancer. Part 2. Perioperative intraperitoneal chemotherapy. Oncology (Williston Park) 2004; 18:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/23\">",
"      Laterza B, Kusamura S, Baratti D, et al. Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma. In Vivo 2009; 23:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/24\">",
"      Blackham AU, Shen P, Stewart JH, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol 2010; 17:2720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/25\">",
"      Yan TD, Edwards G, Alderman R, et al. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma--a prospective study of 70 consecutive cases. Ann Surg Oncol 2007; 14:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/26\">",
"      Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol 2009; 99:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/27\">",
"      Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009; 27:6237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/28\">",
"      Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 2007; 18:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/29\">",
"      Brigand C, Monneuse O, Mohamed F, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol 2006; 13:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/30\">",
"      Deraco M, Casali P, Inglese MG, et al. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol 2003; 83:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/31\">",
"      Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2006; 13:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/32\">",
"      Hassan R, Alexander R, Antman K, et al. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. Ann Oncol 2006; 17:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/33\">",
"      Mongero LB, Beck JR, Kroslowitz RM, et al. Treatment of primary peritoneal mesothelioma by hyperthemic intraperitoneal chemotherapy. Perfusion 1999; 14:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/34\">",
"      Park BJ, Alexander HR, Libutti SK, et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999; 6:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/35\">",
"      Sebbag G, Yan H, Shmookler BM, et al. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000; 87:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/36\">",
"      Deraco M, De Simone M, Rossi CR, et al. An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma. J Exp Clin Cancer Res 2003; 22:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/37\">",
"      Loggie BW, Fleming RA, McQuellon RP, et al. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001; 67:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/38\">",
"      Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006; 32:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/39\">",
"      Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol 2006; 32:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/40\">",
"      Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002; 38:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/41\">",
"      Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/42\">",
"      van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23:6881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/43\">",
"      Campbell NP, Kindler HL. Update on malignant pleural mesothelioma. Semin Respir Crit Care Med 2011; 32:102.",
"     </a>",
"    </li>",
"    <li>",
"     Karthaus M, Frieler F, Vasquez N, et al. Pemetrexed/platinum for patients with advanced malignant peritoneal mesothelioma&mdash;The Beifeld experience (abstract 4151). J Clin Oncol 2006; 24 (18S): 215s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/45\">",
"      Simon GR, Verschraegen CF, J&auml;nne PA, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol 2008; 26:3567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/46\">",
"      Le DT, Deavers M, Hunt K, et al. Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. Cancer Invest 2003; 21:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/47\">",
"      Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000; 18:3912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/48\">",
"      Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009; 63:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/49\">",
"      Varghese S, Chen Z, Bartlett DL, et al. Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer 2011; 117:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/50\">",
"      Foster JM, Radhakrishna U, Govindarajan V, et al. Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. World J Surg Oncol 2010; 8:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/51\">",
"      Hoekstra AV, Riben MW, Frumovitz M, et al. Well-differentiated papillary mesothelioma of the peritoneum: a pathological analysis and review of the literature. Gynecol Oncol 2005; 98:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/52\">",
"      B&uuml;rrig KF, Pfitzer P, Hort W. Well-differentiated papillary mesothelioma of the peritoneum: a borderline mesothelioma. Report of two cases and review of literature. Virchows Arch A Pathol Anat Histopathol 1990; 417:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/53\">",
"      Hejmadi R, Ganesan R, Kamal NG. Malignant transformation of a well-differentiated peritoneal papillary mesothelioma. Acta Cytol 2003; 47:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/54\">",
"      Baratti D, Kusamura S, Nonaka D, et al. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). Ann Surg Oncol 2007; 14:2790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/55\">",
"      Levy AD, Arn&aacute;iz J, Shaw JC, Sobin LH. From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation. Radiographics 2008; 28:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/56\">",
"      Katsube Y, Mukai K, Silverberg SG. Cystic mesothelioma of the peritoneum: a report of five cases and review of the literature. Cancer 1982; 50:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/57\">",
"      Weiss SW, Tavassoli FA. Multicystic mesothelioma. An analysis of pathologic findings and biologic behavior in 37 cases. Am J Surg Pathol 1988; 12:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/58\">",
"      Gonz&aacute;lez-Moreno S, Yan H, Alcorn KW, Sugarbaker PH. Malignant transformation of \"benign\" cystic mesothelioma of the peritoneum. J Surg Oncol 2002; 79:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/48/35593/abstract/59\">",
"      Chua TC, Yan TD, Deraco M, et al. Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma. Br J Surg 2011; 98:60.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 82913 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-BD9846CABD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_48_35593=[""].join("\n");
var outline_f34_48_35593=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H135336372\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H135335340\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H135336267\">",
"      GENERAL PRINCIPLES AND PROGNOSTIC VARIABLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H135336274\">",
"      CYTOREDUCTIVE SURGERY AND INTRAPERITONEAL CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H135336281\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H135336288\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H135336295\">",
"      Results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H135336302\">",
"      Treatment-related toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H135336309\">",
"      SYSTEMIC CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H135336316\">",
"      Pemetrexed plus cisplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8238484\">",
"      Pemetrexed plus carboplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H135336323\">",
"      Pemetrexed plus gemcitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H135336337\">",
"      Cisplatin plus irinotecan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2354825404\">",
"      Other cytotoxic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H135336344\">",
"      Molecularly targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H135336351\">",
"      PERITONEAL MESOTHELIOMA VARIANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H135336358\">",
"      Well-differentiated papillary mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H135336365\">",
"      Multicystic mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H135336372\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/82913\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/82913|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/53/862\" title=\"figure 1\">",
"      OS MPM cytored IPHC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/82913|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/48/5899\" title=\"table 1\">",
"      HIPEC parameters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/40/44685\" title=\"table 2\">",
"      CRS IPHC MPM results",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=related_link\">",
"      Cancer of the appendix and pseudomyxoma peritonei",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/50/32552?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7622?source=related_link\">",
"      Epidemiology of malignant mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17754?source=related_link\">",
"      Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42329?source=related_link\">",
"      Systemic treatment for unresectable malignant pleural mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28312?source=related_link\">",
"      Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_48_35594="Phenytoin: Drug information";
var content_f34_48_35594=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phenytoin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/49/7958?source=see_link\">",
"    see \"Phenytoin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"    see \"Phenytoin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11284327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F209593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dilantin-125&reg;;",
"     </li>",
"     <li>",
"      Dilantin&reg;;",
"     </li>",
"     <li>",
"      Phenytek&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F209594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dilantin&reg;;",
"     </li>",
"     <li>",
"      Novo-Phenytoin;",
"     </li>",
"     <li>",
"      Taro-Phenytoin;",
"     </li>",
"     <li>",
"      Tremytoine Inj",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F209644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Hydantoin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F209598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Phenytoin base (eg, oral suspension, chewable tablets) contains ~8% more drug than phenytoin sodium (~92 mg base is equivalent to 100 mg phenytoin sodium). Dosage adjustments and closer serum monitoring may be necessary when switching dosage forms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Status epilepticus:",
"     </b>",
"     I.V.: Loading dose: Manufacturer recommends 10-15 mg/kg, however, 15-20 mg/kg at a maximum rate of 50 mg/minute is generally recommended (Kalvianines, 2007; Lowenstein, 2005); initial maintenance dose: I.V. or Oral: 100 mg every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anticonvulsant:",
"     </b>",
"     Oral: Loading dose: 15-20 mg/kg; consider prior phenytoin serum concentrations and/or recent dosing history if available; administer oral loading dose in 3 divided doses given every 2-4 hours to decrease GI adverse effects and to ensure complete oral absorption; initial maintenance dose: 300 mg daily in 3 divided doses; may also administer in 1-2 divided doses using extended release formulation; adjust dosage based on individual requirements; usual maintenance dose range: 300-600 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in obesity:",
"     </b>",
"     Loading dose: Use adjusted body weight (ABW) correction based on a pharmacokinetic study of phenytoin loading doses in obese patients (Abernethy, 1985). The larger correction factor (ie, 1.33) is due to a doubling of V",
"     <sub>",
"      d",
"     </sub>",
"     estimated in these obese patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     ABW = [(Actual body weight &ndash; IBW) x 1.33] + IBW",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Maintenance doses should be based on ideal body weight, conventional daily doses with adjustments based upon therapeutic drug monitoring and clinical effectiveness (Abernethy, 1985; Erstad, 2002; Erstad, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F209622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"      see \"Phenytoin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Phenytoin base (eg, oral suspension, chewable tablets) contains ~8% more drug than phenytoin sodium (~92 mg base is equivalent to 100 mg phenytoin sodium). Dosage adjustments and closer serum monitoring may be necessary when switching dosage forms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Status epilepticus:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children:  Loading dose: 15-20 mg/kg, then begin maintenance therapy usually 12 hours after loading dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anticonvulsant (nonemergent use):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loading dose: Children and Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children: Initial maintenance dose: 5 mg/kg/day in 2-3 divided doses; usual maintenance dose range: 4-8 mg/kg/day; maximum daily dose: 300 mg. Some experts suggest higher maintenance doses may be necessary in infant and young children (range: 8-10 mg/kg/day in divided doses).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F209599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F209600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phenytoin level in serum may be difficult to interpret in renal failure. Monitoring of free (unbound) concentrations or adjustment to allow interpretation is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F209601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safe in usual doses in mild liver disease; clearance may be substantially reduced in cirrhosis and plasma level monitoring with dose adjustment advisable. Free phenytoin levels should be monitored closely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F209562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as sodium: 100 mg, 200 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilantin&reg;: 30 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenytek&reg;: 200 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium: 50 mg/mL (2 mL, 5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 100 mg/4 mL (4 mL); 125 mg/5 mL (237 mL, 240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilantin-125&reg;: 125 mg/5 mL (240 mL) [contains ethanol &le;0.6%, sodium benzoate; orange-vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilantin&reg;: 50 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F209547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F11441305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Dilantin&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241523.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241523.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F209567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Suspension: Shake well prior to use. Absorption is impaired when phenytoin suspension is given concurrently to patients who are receiving continuous nasogastric feedings. A method to resolve this interaction is to divide the daily dose of phenytoin and withhold the administration of nutritional supplements for 1-2 hours before and after each phenytoin dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.:",
"     <b>",
"      Avoid",
"     </b>",
"     this route (manufacturer recommends I.M. administration) due to severe risk of local tissue destruction and necrosis; use",
"     <b>",
"      fos",
"     </b>",
"     phenytoin if I.M. administration necessary (Boucher, 1996; Meek, 1999).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Vesicant. Fosphenytoin may be considered for loading in patients who are in status epilepticus, hemodynamically unstable, or develop hypotension/bradycardia with I.V. administration of phenytoin. Although, phenytoin may be administered by direct I.V. injection, it is preferable that phenytoin be administered via infusion pump either undiluted or diluted in normal saline as an I.V. piggyback (IVPB) to prevent exceeding the maximum infusion rate (monitor closely for extravasation during infusion). The maximum rate of I.V. administration is 50 mg/minute in adults. Highly sensitive patients (eg, elderly, patients with pre-existing cardiovascular conditions) should receive phenytoin more slowly (eg, 20 mg/minute) (Meek, 1999). In neonates, the manufacturer recommends a maximum rate of 1-3 mg/kg/minute; however, a lower maximum rate of 0.5-1 mg/kg/minute is used clinically (Sankar, 2010; Shields, 1989). An in-line 0.22-5 micron filter is recommended for IVPB solutions due to the high potential for precipitation of the solution. Avoid extravasation. Following I.V. administration, NS should be injected through the same needle or I.V. catheter to prevent irritation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     pH: 10.0-12.3",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     SubQ: SubQ administration is not recommended because of the possibility of local tissue damage (due to high pH).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F209651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Incompatible",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, fat emulsion 10%,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Esmolol, famotidine, fluconazole, foscarnet.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, cefepime, ceftazidime, cimetidine, ciprofloxacin, diltiazem, enalaprilat, fenoldopam, fentanyl, heparin, heparin with hydrocortisone sodium succinate, hydromorphone, linezolid, methadone, micafungin, morphine,  potassium chloride, propofol, sufentanil, theophylline, vasopressin, vitamin B complex with C.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Pantoprazole, tacrolimus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Hydromorphone, ondansetron, pantoprazole, sufentanil.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F209566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of generalized tonic-clonic (grand mal), complex partial seizures; prevention of seizures following neurosurgery",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14960593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of early (within 1 week) post-traumatic seizures (PTS) following traumatic brain injury",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F209653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Phenytoin may be confused with phenelzine, phentermine, PHENobarbital",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dilantin&reg; may be confused with Dilaudid&reg;, diltiazem, Dipentum&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dilantin [U.S., Canada, and multiple international markets] may be confused with Dolantine brand name for pethidine [Belgium]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F209642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. effects: Hypotension, bradycardia, cardiac arrhythmia, cardiovascular collapse (especially with rapid I.V. use), venous irritation and pain, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Effects not related to plasma phenytoin concentrations:",
"     </b>",
"     Hypertrichosis, gingival hypertrophy, thickening of facial features, carbohydrate intolerance, folic acid deficiency, peripheral neuropathy, vitamin D deficiency, osteomalacia, systemic lupus erythematosus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentration-related effects:",
"     </b>",
"     Nystagmus, blurred vision, diplopia, ataxia, slurred speech, dizziness, drowsiness, lethargy, coma, rash, fever, nausea, vomiting, gum tenderness, confusion, mood changes, folic acid depletion, osteomalacia, hyperglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Related to elevated concentrations:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;20 mcg/mL: Far lateral nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;30 mcg/mL: 45&deg; lateral gaze nystagmus and ataxia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;40 mcg/mL: Decreased mentation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;100 mcg/mL: Death",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, cardiac arrhythmia, cardiovascular collapse, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, headache, insomnia, psychiatric changes, slurred speech",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, gingival hyperplasia, enlargement of lips, nausea, taste disturbance, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Peyronie&rsquo;s disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, granulocytopenia, leukopenia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: I.V. administration: Inflammation, irritation, necrosis, sloughing, tenderness, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, peripheral neuropathy, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rarely seen effects: Anaphylaxis, blood dyscrasias, coarsening of facial features, DRESS, dyskinesias, hepatitis, Hodgkin lymphoma,, hypertrichosis, immunoglobulin abnormalities, lymphadenopathy, lymphoma, macrocytosis, megaloblastic anemia, periarteritis nodosa,  pseudolymphoma, SLE-like syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, venous irritation and pain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F209570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phenytoin, other hydantoins, or any component of the formulation; concurrent use of delavirdine (due to loss of virologic response and possible resistance to delavirdine or other non-nucleoside reverse transcriptase inhibitors [NNRTIs])",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     I.V.: Sinus bradycardia, sinoatrial block, second- and third-degree heart block, Adams-Stokes syndrome",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F209551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: A spectrum of hematologic effects have been reported with use (eg, agranulocytosis, neutropenia, leukopenia, thrombocytopenia, pancytopenia, and anemias); patients with a previous history of adverse hematologic reaction to any drug may be at increased risk. Early detection of hematologic change is important; advise patients of early signs and symptoms including fever, sore throat, mouth ulcers, infections, easy bruising, petechial or purpuric hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone effects: Chronic use of phenytoin has been associated with decreased bone mineral density (osteopenia, osteoporosis, and osteomalacia) and bone fractures. Chronic use may result in decreased vitamin D concentrations due to hepatic enzyme induction and may lead to hypocalcemia and hypophosphatemia; monitor as appropriate and consider implementing vitamin D and calcium supplementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: Phenytoin must be administered slowly. Intravenous administration should not exceed 50 mg/minute in adult patients. In pediatric patients, intravenous administration rate should not exceed 1-3 mg/kg/minute or 50 mg/minute whichever is slower.",
"     </b>",
"     Hypotension and severe cardiac arrhythmias (eg, heart block, ventricular tachycardia, ventricular fibrillation) may occur with rapid administration; adverse cardiac events have been reported at or below the recommended infusion rate. Cardiac monitoring is necessary during and after administration of intravenous phenytoin; reduction in rate of administration or discontinuation of infusion may be necessary. For nonemergency use, intravenous phenytoin should be administered more slowly; the use of oral phenytoin should be used whenever possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Severe reactions, including toxic epidermal necrolysis and Stevens-Johnson syndromes, although rarely reported, have resulted in fatalities; drug should be discontinued if there are any signs of rash and patient should be evaluated for signs and symptoms of drug reaction with eosinophilia and systemic symptoms (DRESS). Data suggests a genetic susceptibility for serious skin reactions in patients of Asian descent (see \"Special populations\" below).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity syndrome: Acute hepatotoxicity associated with a hypersensitivity syndrome characterized by fever, skin eruptions, and lymphadenopathy has been reported to occur within the first 2 months of treatment; discontinue if skin rash or lymphadenopathy occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with underlying cardiac disease; I.V. use is contraindicated in patients with sinus bradycardia, sinoatrial block, or second and third degree heart block.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoalbuminemia: Use with caution in patients with any condition associated with low serum albumin levels, which will increase the free fraction of phenytoin in the serum and, therefore, the pharmacologic response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypothyroidism: Use with caution in patients with hypothyroidism; phenytoin may alter thyroid hormone serum concentrations (with chronic administration).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: May increase frequency of petit mal seizures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asian ancestry: Asian patients with the variant",
"     <i>",
"      HLA-B*1502",
"     </i>",
"     may be at an increased risk of developing Stevens-Johnson syndrome and/or toxic epidermal necrolysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in patients who are debilitated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injectable: I.V. form may cause soft tissue irritation and inflammation, and skin necrosis at I.V. site; avoid I.V. administration in small veins. The \"purple glove syndrome\" (ie, discoloration with edema and pain of distal limb) may occur following peripheral I.V. administration of phenytoin. This syndrome may or may not be associated with drug extravasation. Symptoms may resolve spontaneously; however, skin necrosis and limb ischemia may occur; interventions such as fasciotomies, skin grafts, and amputation (rare) may be required. To decrease the risk of this syndrome, inject phenytoin slowly and directly into a large vein through a large gauge needle or I.V. catheter; follow with NS flushes through the same needle or I.V. catheter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serum concentrations:  Sedation, confusional states, or cerebellar dysfunction (loss of motor coordination) may occur at higher total serum concentrations, or at lower total serum concentrations when the free fraction of phenytoin is increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F209639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP2C9 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP2B6 (strong), CYP2C19 (strong), CYP2C8 (strong), CYP2C9 (strong), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F209556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Anticonvulsants (Hydantoin) may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the CNS depressant effect of Phenytoin. Alcohol (Ethyl) may increase the serum concentration of Phenytoin. This may be particularly applicable with acute, heavy alcohol consumption. Alcohol (Ethyl) may decrease the serum concentration of Phenytoin. This may be particularly applicable with chronic, heavy alcohol consumption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May increase the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Phenytoin may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Phenytoin.  Management: Concomitant therapy with itraconazole, voriconazole, or ketoconazole and phenytoin should probably be avoided, as antifungal failure is likely.  Consider selecting alternative antifungal therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: Phenytoin may enhance the CNS depressant effect of Barbiturates. Barbiturates may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines: May increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <b>",
"      Exceptions:",
"     </b>",
"     ALPRAZolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: Phenytoin may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Phenytoin may decrease the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May increase the serum concentration of Phenytoin. Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: Phenytoin may decrease the serum concentration of Canagliflozin.  Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capecitabine: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Phenytoin. CarBAMazepine may increase the serum concentration of Phenytoin. Possibly by competitive inhibition at sites of metabolism. Phenytoin may decrease the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of Anticonvulsants (Hydantoin). Specifically, osteomalacia and rickets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caspofungin: Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.  Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CeFAZolin: May decrease the protein binding of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May decrease the metabolism of Anticonvulsants (Hydantoin). Anticonvulsants (Hydantoin) may decrease the serum concentration of Chloramphenicol. Increased chloramphenicol concentrations have also been seen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May enhance the adverse/toxic effect of Anticonvulsants (Hydantoin). Cimetidine may increase the serum concentration of Anticonvulsants (Hydantoin). Management: Consider using an alternative H",
"     <sub>",
"      2",
"     </sub>",
"     -antagonist to avoid this interaction. Monitor for toxic effects of hydantoin anticonvulsants if cimetidine is initiated/dose increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ciprofloxacin (Systemic): May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Phenytoin may decrease the serum concentration of CloZAPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: Fosphenytoin-Phenytoin may decrease the serum concentration of Cobicistat.  Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Phenytoin. Management: Administer phenytoin at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Phenytoin may diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Phenytoin may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cosyntropin: May enhance the hepatotoxic effect of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Phenytoin may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inducers (Strong) may increase the metabolism of CYP2B6 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inducers (Strong) may increase the metabolism of CYP2C19 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inducers (Strong) may increase the metabolism of CYP2C8 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inducers (Strong) may increase the metabolism of CYP2C9 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: Phenytoin may decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Phenytoin may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Delavirdine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May decrease the serum concentration of Phenytoin. Total phenytoin concentrations may be affected more than free phenytoin concentrations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inducers (Strong) may decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Phenytoin may decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May increase the serum concentration of Phenytoin. Management: Avoid concomitant use of disulfiram and phenytoin when possible.  Phenytoin dose adjustment will likely be necessary when starting and/or stopping concurrent disulfiram.  Monitor phenytoin response and concentrations closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxycycline: Phenytoin may decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Fosphenytoin-Phenytoin may decrease the serum concentration of Elvitegravir.  Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of Fosphenytoin-Phenytoin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethosuximide: May enhance the CNS depressant effect of Phenytoin. Ethosuximide may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Ethosuximide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: Phenytoin may decrease the serum concentration of Etoposide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide Phosphate: Phenytoin may decrease the serum concentration of Etoposide Phosphate. Phenytoin may increase the metabolism, via CYP isoenzymes, of etoposide phosphate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Phenytoin may decrease the serum concentration of Etravirine.  Management: The manufacturer of etravirine states these drugs should not be used in combination",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Felbamate. Management: Decreased phenytoin dose will likely be needed when adding felbamate; some reports suggest an empiric 20% decrease in phenytoin dose. Additional reductions may be needed if felbamate dose is increased or as otherwise guided by monitoring.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floxuridine: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flunarizine: Phenytoin may decrease the serum concentration of Flunarizine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Systemic): May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Topical): May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FLUoxetine: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Folic Acid: May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May decrease the serum concentration of Phenytoin. The active amprenavir metabolite is likely responsible for this effect. Phenytoin may increase the serum concentration of Fosamprenavir. Specifically, phenytoin may increase the concentration of the active metabolite amprenavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halothane: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Phenytoin may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pitavastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: Phenytoin may decrease the serum concentration of Irinotecan. Concentrations of the active metabolite SN-38 may also be reduced.  Management: Change to a non-enzyme inducing anticonvulsant, when clinically possible, at least 2 weeks prior to beginning irinotecan.  Dosage increases for irinotecan may be needed when used with phenytoin, but specific dosing guidelines are not available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May increase the serum concentration of Phenytoin. Management: Consider alternatives. If concomitant therapy cannot be avoided, monitor for increased phenytoin concentrations/effects with isoniazid initiation/dose increase, or decreased concentrations/effects with isoniazid discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lacosamide: Phenytoin may decrease the serum concentration of Lacosamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Phenytoin may decrease the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Phenytoin may diminish the therapeutic effect of Levodopa.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levomefolate: May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Phenytoin may enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Phenytoin may diminish the diuretic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Lopinavir. Management: The manufacturer of lopinavir/ritonavir recommends avoiding once-daily administration if used together with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mebendazole: Phenytoin may decrease the serum concentration of Mebendazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Phenytoin may decrease the serum concentration of Meperidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Phenytoin may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: Phenytoin may decrease the serum concentration of MethylPREDNISolone.  Management: Consider an alternative corticosteroid. If this combination cannot be avoided, monitor for diminished methylprednisolone effects during phenytoin treatment, and increased methylprednisolone effects following phenytoin discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): May increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of MetroNIDAZOLE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: Phenytoin may decrease the serum concentration of Metyrapone. The oral metyrapone test would thus be unreliable unless the metapyrone dosage was substantially increased (e.g., 750 mg every 2 hours).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mexiletine: Phenytoin may decrease the serum concentration of Mexiletine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Fosphenytoin-Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Fosphenytoin-Phenytoin may decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. OXcarbazepine may increase the serum concentration of Fosphenytoin-Phenytoin.  Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: Fosphenytoin-Phenytoin may decrease the serum concentration of Perampanel.  Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used with phenytoin/fosphenytoin.  Patients receiving this combination should be followed closely for response, especially with any changes to phenytoin/fosphenytoin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PrednisoLONE (Systemic): Phenytoin may decrease the serum concentration of PrednisoLONE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PredniSONE: Phenytoin may decrease serum concentrations of the active metabolite(s) of PredniSONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Phenytoin may increase the metabolism of Primidone. The ratio of primidone:phenobarbital is thus changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Phenytoin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dexlansoprazole; Esomeprazole; Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridoxine: May increase the metabolism of Phenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QUEtiapine: Phenytoin may decrease the serum concentration of QUEtiapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Phenytoin may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Phenytoin may decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Phenytoin may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: Phenytoin may decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: Phenytoin may decrease the serum concentration of Rufinamide. Rufinamide may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sertraline: Phenytoin may decrease the serum concentration of Sertraline. Sertraline may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Phenytoin may decrease the serum concentration of Sirolimus.  Management: Monitor for decreased sirolimus serum concentrations if phenytoin is initiated/dose increased. Monitor for increased sirolimus concentrations with phenytoin discontinuation/dose decrease. Sirolimus dose adjustments may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Phenytoin may decrease the serum concentration of Tacrolimus (Systemic). Tacrolimus (Systemic) may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Phenytoin may decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Phenytoin. Telaprevir may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Phenytoin may decrease the serum concentration of Temsirolimus. Concentrations of the active metabolite, sirolimus, are also likely to be decreased (and maybe to an even greater degree).  Management: Temsirolimus prescribing information recommends against coadministration with strong CYP3A4 inducers such as phenytoin; however, if concurrent therapy is necessary, an increase in temsirolimus adult dose to 50 mg/week should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teniposide: Phenytoin may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with phenytoin and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Phenytoin may decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticlopidine: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Phenytoin may decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Phenytoin may decrease the serum concentration of Topiramate. Topiramate may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Phenytoin may decrease the serum concentration of TraZODone. TraZODone may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Phenytoin may increase the metabolism of Valproic Acid. A hepatotoxic metabolite of valproic acid may result. Valproic Acid may decrease the serum concentration of Phenytoin. Continued therapy usually yields a normalization (or slight increase) of serum phenytoin concentrations.  Free phenytoin concentrations, however, tend to remain relatively stable (possibly increased with continued therapy).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vecuronium: Phenytoin may enhance the therapeutic effect of Vecuronium. Phenytoin may diminish the therapeutic effect of Vecuronium. Phenytoin may decrease the serum concentration of Vecuronium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vigabatrin: May decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine: Phenytoin may decrease the serum concentration of VinCRIStine. VinCRIStine may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Phenytoin may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Phenytoin.  Management: Anticoagulant dose adjustment will likely be necessary when phenytoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zonisamide: Phenytoin may decrease the serum concentration of Zonisamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F209588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute use: Ethanol inhibits metabolism of phenytoin and may also increase CNS depression. Management: Avoid or limit ethanol. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chronic use: Ethanol stimulates metabolism of phenytoin. Management: Avoid or limit ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Phenytoin serum concentrations may be altered if taken with food. If taken with enteral nutrition, phenytoin serum concentrations may be decreased. Tube feedings decrease bioavailability. Phenytoin may decrease calcium, folic acid, and vitamin D levels. Supplementing folic acid may lower the seizure threshold. Management: Hold tube feedings 1-2 hours before and 1-2 hours after phenytoin administration. Do not supplement folic acid. Consider vitamin D supplementation. Take preferably on an empty stomach.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Evening primrose may decrease the seizure threshold; other herbal medications may increase CNS depression. Management: Avoid evening primrose, valerian, St John's wort, kava kava, and gotu kola.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F209558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F209573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phenytoin crosses the placenta. Congenital malformations (including a pattern of malformations termed the &ldquo;fetal hydantoin syndrome&rdquo; or &ldquo;fetal anticonvulsant syndrome&rdquo;) have been reported in infants. Isolated cases of malignancies (including neuroblastoma) and coagulation defects in the neonate following delivery have also been reported. Epilepsy itself, the number of medications, genetic factors, or a combination of these probably influence the teratogenicity of anticonvulsant therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Total plasma concentrations of phenytoin are decreased by 56% in the mother during pregnancy; unbound plasma (free) concentrations are decreased by 31%. Because protein binding is decreased, monitoring of unbound plasma concentrations is recommended. Concentrations should be monitored through the 8th week postpartum. The use of folic acid throughout pregnancy and vitamin K during the last month of pregnancy is recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to phenytoin during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F209606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F209574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phenytoin is excreted in breast milk; however, the amount to which the infant is exposed is considered small. The manufacturers of phenytoin do not recommend breast-feeding during therapy. Women should be counseled of the possible risks and benefits associated with breast-feeding while on phenytoin.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F209575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Folic acid: Phenytoin may decrease mucosal uptake of folic acid; to avoid folic acid deficiency and megaloblastic anemia, some clinicians recommend giving patients on anticonvulsants prophylactic doses of folic acid and cyanocobalamin. Folic acid 0.5 mg/day has been shown to reduce the incidence of phenytoin-induced gingival overgrowth in children (Arya, 2011). However, folate supplementation may increase seizures in some patients (dose dependent). Discuss with healthcare provider prior to using any supplements.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Calcium: Hypocalcemia has been reported in patients taking prolonged high-dose therapy with an anticonvulsant. Some clinicians have given an additional 4000 units/week of vitamin D (especially in those receiving poor nutrition and getting no sun exposure) to prevent hypocalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vitamin D: Phenytoin interferes with vitamin D metabolism and osteomalacia may result; may need to supplement with vitamin D",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tube feedings: Tube feedings decrease phenytoin absorption. To avoid decreased serum levels with continuous NG feeds, hold feedings for 1-2 hours prior to and 1-2 hours after phenytoin administration, if possible. There is a variety of opinions on how to administer phenytoin with enteral feedings. Be",
"     <b>",
"      consistent",
"     </b>",
"     throughout therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F209572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Dilantin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $56.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $65.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Phenytek Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (30): $42.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $62.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Phenytoin Sodium Extended Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $33.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (30): $24.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $35.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Dilantin Infatabs Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $61.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Phenytoin Infatabs Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $52.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Phenytoin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $52.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Phenytoin Sodium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (2 mL): $1.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Dilantin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg/5 mL (237 mL): $81.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Phenytoin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg/5 mL (237 mL): $36.97",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F209560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, liver function; suicidality (eg, suicidal thoughts, depression, behavioral changes); plasma phenytoin concentrations (if available, free phenytoin concentrations should be obtained in patients with renal impairment and/or hypoalbuminemia; if free phenytoin concentrations are unavailable, the adjusted total concentration may be determined based upon equations in adult patients). Trough concentrations are generally recommended for routine monitoring.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Additional monitoring with I.V. use: Continuous cardiac monitoring (rate, rhythm, blood pressure) and observation during administration recommended; blood pressure and pulse should be monitored every 15 minutes for 1 hour after administration (Meek, 1999); infusion site reactions",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F209563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Timing of serum samples: Because it is slowly absorbed, peak blood levels may occur 4-8 hours after ingestion of an oral dose. The serum half-life varies with the dosage and the drug follows Michaelis-Menten kinetics. The average adult half-life is about 24 hours. Steady-state concentrations are reached in 5-10 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Children and Adults: Toxicity is measured clinically, and some patients require levels outside the suggested therapeutic range",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic range:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Total phenytoin: 10-20 mcg/mL (children and adults), 8-15 mcg/mL (neonates)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Concentrations of 5-10 mcg/mL may be therapeutic for some patients but concentrations &lt;5 mcg/mL are not likely to be effective",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50% of patients show decreased frequency of seizures at concentrations &gt;10 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     86% of patients show decreased frequency of seizures at concentrations &gt;15 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Add another anticonvulsant if satisfactory therapeutic response is not achieved with a phenytoin concentration of 20 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Free phenytoin: 1-2.5 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Total phenytoin:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Toxic:",
"     </i>",
"     &gt;30 mcg/mL (SI: &gt;119 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Lethal:",
"     </i>",
"     &gt;100 mcg/mL (SI: &gt;400 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      When to draw levels:",
"     </b>",
"     This is dependent on the disease state being treated and the clinical condition of the patient",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Key points:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Slow absorption of extended capsules and prolonged half-life minimize fluctuations between peak and trough concentrations, timing of sampling not crucial",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Trough concentrations are generally recommended for routine monitoring. Daily levels are not necessary and may result in incorrect dosage adjustments. If it is determined essential to monitor free phenytoin concentrations, concomitant monitoring of total phenytoin concentrations is not necessary and expensive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     After a loading dose: If rapid therapeutic levels are needed, initial levels may be drawn after 1 hour (I.V. loading dose) or within 24 hours (oral loading dose) to aid in determining maintenance dose or need to reload.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rapid achievement: Draw within 2-3 days of therapy initiation to ensure that the patient's metabolism is not remarkably different from that which would be predicted by average literature-derived pharmacokinetic parameters; early levels should be used cautiously in design of new dosing regimens",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Second concentration: Draw within 6-7 days with subsequent doses of phenytoin adjusted accordingly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If plasma concentrations have not changed over a 3- to 5-day period, monitoring interval may be increased to once weekly in the acute clinical setting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     In stable patients requiring long-term therapy, generally monitor levels at 3- to 12-month intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Adjustment of serum concentration:",
"     </b>",
"     See tables.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Although it is ideal to obtain free phenytoin concentrations to assess serum concentrations in patients with hypoalbuminemia or renal failure (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;10 mL/minute), it may not always be possible. If free phenytoin concentrations are unavailable, the following equations may be utilized in adult patients.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Adjustment of Serum Concentration in Adults With Low Serum Albumin",
"     </caption>",
"     <col align=\"center\" width=\"120\">",
"     </col>",
"     <col align=\"center\" width=\"87\">",
"     </col>",
"     <col align=\"center\" width=\"87\">",
"     </col>",
"     <col align=\"center\" width=\"88\">",
"     </col>",
"     <col align=\"center\" width=\"88\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Measured Total Phenytoin Concentration",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mcg/mL)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         Patient's Serum Albumin (g/dL)",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.5",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\" colspan=\"4\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Adjusted Total Phenytoin Concentration (mcg/mL)",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Adjusted concentration = measured total concentration divided by [(0.2 x albumin) + 0.1].",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         13",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         14",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         17",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         19",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         21",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Adjustment of Serum Concentration in Adults With Renal Failure (Cl",
"      <sub>",
"       cr",
"      </sub>",
"      &le;10 mL/min)",
"     </caption>",
"     <col align=\"center\" width=\"120\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Measured Total Phenytoin Concentration",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mcg/mL)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         Patient's Serum Albumin (g/dL)",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.5",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         Adjusted Total Phenytoin Concentration (mcg/mL)",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Adjusted concentration = measured total concentration divided by [(0.1 x albumin) + 0.1].",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         13",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         14",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         17",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         22",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         29",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         33",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         33",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         38",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         43",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F209576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aleviatin (JP, TW);",
"     </li>",
"     <li>",
"      Antisacer (PT);",
"     </li>",
"     <li>",
"      Clerin (PY);",
"     </li>",
"     <li>",
"      Clerin LR (PY);",
"     </li>",
"     <li>",
"      Cumatil (CO);",
"     </li>",
"     <li>",
"      Di-Hydan (FR, LU);",
"     </li>",
"     <li>",
"      Difetoin (HR);",
"     </li>",
"     <li>",
"      Dilantin (AU, FR, HK, ID, IN, MY, NZ, PH, PK, SG, TH, VE);",
"     </li>",
"     <li>",
"      Dintoina (IT);",
"     </li>",
"     <li>",
"      Diphedan (HU);",
"     </li>",
"     <li>",
"      Ditoin (HK, MY, TH);",
"     </li>",
"     <li>",
"      Epamin (AR, BO, BR, CN, CO, CR, DO, EC, GT, HN, MX, NI, PA, PE, PR, SV, VE);",
"     </li>",
"     <li>",
"      Epanutin (AE, AT, BE, BF, BH, BJ, CI, CY, CZ, DE, EG, ES, ET, FI, GB, GH, GM, GN, GR, HU, IE, IL, IQ, IR, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PL, QA, SA, SC, SD, SE, SL, SN, SY, TN, TR, TZ, UG, UY, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Epilan-D (AT, BG, CZ);",
"     </li>",
"     <li>",
"      Epinat (NO);",
"     </li>",
"     <li>",
"      Eptoin (IN);",
"     </li>",
"     <li>",
"      Felantin (PE);",
"     </li>",
"     <li>",
"      Fenatoin NM (SE);",
"     </li>",
"     <li>",
"      Fenidantoin S (MX);",
"     </li>",
"     <li>",
"      Fenitin (PH);",
"     </li>",
"     <li>",
"      Fenitoina (ES);",
"     </li>",
"     <li>",
"      Fenitoina Rubio (ES);",
"     </li>",
"     <li>",
"      Fenitron (MX);",
"     </li>",
"     <li>",
"      Fenytoin (DE, DK);",
"     </li>",
"     <li>",
"      Fomiken (MX);",
"     </li>",
"     <li>",
"      Hidanil (CO);",
"     </li>",
"     <li>",
"      Hidanto&iacute;na (MX);",
"     </li>",
"     <li>",
"      Hydantin (FI);",
"     </li>",
"     <li>",
"      Hydantoin (KP);",
"     </li>",
"     <li>",
"      Hydantol (JP);",
"     </li>",
"     <li>",
"      Ikaphen (ID);",
"     </li>",
"     <li>",
"      Kutoin (ID);",
"     </li>",
"     <li>",
"      Lantidin (PH);",
"     </li>",
"     <li>",
"      Lehydan (SE);",
"     </li>",
"     <li>",
"      Neosidantoina (ES);",
"     </li>",
"     <li>",
"      Pepsytoin-100 (TH);",
"     </li>",
"     <li>",
"      Phenhydan (AT, CH, DE, EE, HU, LU);",
"     </li>",
"     <li>",
"      Phenilep (ID);",
"     </li>",
"     <li>",
"      Phenlin (TW);",
"     </li>",
"     <li>",
"      Pyoredol (AR, FR);",
"     </li>",
"     <li>",
"      Sinergina (ES);",
"     </li>",
"     <li>",
"      Utoin (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F209550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses; prolongs effective refractory period and suppresses ventricular pacemaker automaticity, shortens action potential in the heart",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F209569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: ~0.5-1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Slow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: Premature: 1-1.2 L/kg; Full-term: 0.8-0.9 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 0.7-0.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 0.7 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 0.6-0.7 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: &ge;80% (&le;20% free)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: &ge;85% (&le;15% free)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 90% to 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Others: Decreased protein binding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Disease states resulting in a decrease in serum albumin concentration",
"     </b>",
"     : Burns, hepatic cirrhosis, nephrotic syndrome, pregnancy, cystic fibrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Disease states resulting in an apparent decrease in affinity of phenytoin for serum albumin",
"     </b>",
"     : Renal failure, jaundice (severe), other drugs (displacers), hyperbilirubinemia (total bilirubin &gt;15 mg/dL), Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute (unbound fraction is increased two- to threefold in uremia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Follows dose-dependent capacity-limited (Michaelis-Menten) pharmacokinetics with increased V",
"     <sub>",
"      max",
"     </sub>",
"     (ie, metabolic capacity) in infants &gt;6 months of age and children versus adults; major metabolite (via oxidation), HPPA, undergoes enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Formulation dependent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Range: 7-42 hours;",
"     <b>",
"      Note:",
"     </b>",
"     Elimination is not first-order (ie, follows Michaelis-Menten pharmacokinetics); half-life increases with increasing phenytoin concentrations; best described using parameters such as V",
"     <sub>",
"      max",
"     </sub>",
"     (metabolic capacity) and Km (constant equal to the concentration at which the rate of metabolism is",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of V",
"     <sub>",
"      max",
"     </sub>",
"     ).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum (formulation dependent): Oral: Extended-release capsule: 4-12 hours; Immediate release preparation: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;5% as unchanged drug); as glucuronides",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Highly variable, dependent upon intrinsic hepatic function and dose administered; increased clearance and decreased serum concentrations with febrile illness",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abernethy DR and Greenblatt DJ, &ldquo;Phenytoin Disposition in Obesity. Determination of Loading Dose,&rdquo;",
"      <i>",
"       Arch Neurol",
"      </i>",
"      , 1985, 42(5):468-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/3994563/pubmed\" id=\"3994563\" target=\"_blank\">",
"        3994563",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arya R, Gulati S, Kabra M, et al, &ldquo;Folic Acid Supplementation Prevents Phenytoin-induced Gingival Overgrowth in Children,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2011, 76(15):1338-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/21482950/pubmed\" id=\"21482950\" target=\"_blank\">",
"        21482950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Au Yeung SC and Ensom MH, &ldquo;Phenytoin and Enteral Feedings: Does Evidence Support an Interaction?&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(7-8):896-905.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/10928402/pubmed\" id=\"10928402\" target=\"_blank\">",
"        10928402",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bauer LA and Blouin RA, &ldquo;Phenytoin Michaelis-Menten Pharmacokinetics in Caucasian Pediatric Patients,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1983, 8(6):545-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/6653035/pubmed\" id=\"6653035\" target=\"_blank\">",
"        6653035",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berigan T and Watt TJ, &ldquo;Dilantin&reg; Toxicity Presenting as Mutism Following Severe Head Injury: Case Report,&rdquo;",
"      <i>",
"       Mil Med",
"      </i>",
"      , 1994, 159(7):533-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/7816230/pubmed\" id=\"7816230\" target=\"_blank\">",
"        7816230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Black J, Hannaman T, and Malone C, &ldquo;The Relationship of Serum Albumin Level to Phenytoin Toxicity,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1987, 27(3):249-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/3680582/pubmed\" id=\"3680582\" target=\"_blank\">",
"        3680582",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bleck TB, Seizures, Stroke, and Other Neurologic Emergencies. In: Zimmerman JL, Roberts PR, eds.",
"      <i>",
"       Multidisciplinary Critical Care Review",
"      </i>",
"      , Des Plains, IL: Society of Critical Care Medicine; 2003:325-34.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boucher BA, Feler CA, Dean JC, et al, \"The Safety, Tolerability, and Pharmacokinetics of Fosphenytoin After Intramuscular and Intravenous Administration in Neurosurgery Patients,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1996, 16(4):638-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/8840370/pubmed\" id=\"8840370\" target=\"_blank\">",
"        8840370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, &ldquo;Guidelines for the Management of Severe Traumatic Brain Injury,&rdquo;",
"      <i>",
"       J Neurotrauma",
"      </i>",
"      , 2007, 24(Suppl 1):1-106.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/17511534/pubmed\" id=\"17511534\" target=\"_blank\">",
"        17511534",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chang BS and Lowenstein DH, &ldquo;Practice Parameter: Antiepileptic Drug Prophylaxis in Severe Traumatic Brain Injury: Report of the Quality Standards Subcommittee of the American Academy of Neurology,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2003, 60(1):10-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/12525711/pubmed\" id=\"12525711\" target=\"_blank\">",
"        12525711",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chapman MG, Smith M, and Hirsch NP, &ldquo;Status Epilepticus,&rdquo;",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2001, 56(7):648-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/11437765/pubmed\" id=\"11437765\" target=\"_blank\">",
"        11437765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chiba K, Ishizaki T, Miura H, et al, &ldquo;Michaelis-Menten Pharmacokinetics of Diphenylhydantoin and Application in the Pediatric Age Patient,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1980, 96(3 Pt 1):479-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/7359247/pubmed\" id=\"7359247\" target=\"_blank\">",
"        7359247",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dela Cruz FG, Kanter MZ, Fischer JH, et al, &ldquo;Efficacy of Individualized Phenytoin Sodium Loading Doses Administered by Intravenous Infusion,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1988, 7(3):219-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/3356118/pubmed\" id=\"3356118\" target=\"_blank\">",
"        3356118",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dooley G and Vasan N, &ldquo;Dilantin&reg; Hyperplasia: A Review of the Literature,&rdquo;",
"      <i>",
"       J N Z Soc Periodontol",
"      </i>",
"      , 1989, 68:19-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/2701005/pubmed\" id=\"2701005\" target=\"_blank\">",
"        2701005",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doyle MF, Anderson S, Cerrezuela C, et al, &ldquo;Sezary Syndrome Associated With Phenytoin Therapy,&rdquo;",
"      <i>",
"       Acta Haematol",
"      </i>",
"      , 1994, 92(4):204-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/7701919/pubmed\" id=\"7701919\" target=\"_blank\">",
"        7701919",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erstad BL, &ldquo;Dosing of Medications in Morbidly Obese Patients in the Intensive Care Unit Setting,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2004, 30(1):18-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/14625670/pubmed\" id=\"14625670\" target=\"_blank\">",
"        14625670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erstad BL, &ldquo;Which Weight for Weight-Based Dosage Regimens in Obese Patients?&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2002, 59:(21)2105-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/12434728/pubmed\" id=\"12434728\" target=\"_blank\">",
"        12434728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hagg S and Spigset O, &ldquo;Anticonvulsant Use During Lactation,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2000, 22(6):425-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/10877037/pubmed\" id=\"10877037\" target=\"_blank\">",
"        10877037",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hans P, Brichant JF, Pieron F, et al, &ldquo;Elevated Plasma Alpha 1-Acid Glycoprotein Levels: Lack of Connection to Resistance to Vecuronium Blockade Induced by Anticonvulsant Therapy,&rdquo;",
"      <i>",
"       J Neurosurg Anesthesiol",
"      </i>",
"      , 1997, 9(1):3-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/9016432/pubmed\" id=\"9016432\" target=\"_blank\">",
"        9016432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iacopino AM, Doxey D, Cutler CW, et al, &ldquo;Phenytoin and Cyclosporine A Specifically Regulate Macrophage Phenotype and Expression of Platelet-Derived Growth Factor and Interleukin-1",
"      <i>",
"       In Vitro",
"      </i>",
"      and",
"      <i>",
"       In Vivo",
"      </i>",
"      : Possible Molecular Mechanism of Drug-Induced Gingival Hyperplasia,&rdquo;",
"      <i>",
"       J Periodontol",
"      </i>",
"      , 1997, 68(1):73-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/9029455/pubmed\" id=\"9029455\" target=\"_blank\">",
"        9029455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kalviainen R, &ldquo;Status Epilepticus Treatment Guidelines,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2007, 48(Suppl 8):99-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/18330014/pubmed\" id=\"18330014\" target=\"_blank\">",
"        18330014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kerrick JM, Wolff DL, and Graves NM, &ldquo;Predicting Unbound Phenytoin Concentrations in Patients Receiving Valproic Acid: A Comparison of Two Prediction Methods,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(5):470-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/7655129/pubmed\" id=\"7655129\" target=\"_blank\">",
"        7655129",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kochanek PM, Carney N, Adelson PD, et al, &ldquo;Guidelines for the Acute Medical Management of Severe Traumatic Brain Injury in Infants, Children, and Adolescents -- Second Edition,&rdquo;",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2012, 13(Suppl 1):1-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/22217782/pubmed\" id=\"22217782\" target=\"_blank\">",
"        22217782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lombardi TP, Gailey RA, and Bryant BG, &ldquo;Phenytoin Overdose in Neonate Attributable to Product Packaging Similarities,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1989, 46(10):1999-2000.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/2816946/pubmed\" id=\"2816946\" target=\"_blank\">",
"        2816946",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lowenstein DH, &ldquo;Treatment Options for Status Epilepticus,&rdquo;",
"      <i>",
"       Curr Opin Pharmacol",
"      </i>",
"      , 2005, 5(3):334-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/15907922/pubmed\" id=\"15907922\" target=\"_blank\">",
"        15907922",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Manno EM, &ldquo;New Management Strategies in the Treatment of Status Epilepticus,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 2003, 78(4):508-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/12683704/pubmed\" id=\"12683704\" target=\"_blank\">",
"        12683704",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mansur LI, Murrow RW, Garrelts JC, et al, &ldquo;Rebound of Plasma Free Phenytoin Concentration Following Plasmapheresis in a Patient With Thrombotic Thrombocytopenic Purpura,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(6):592-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/7663032/pubmed\" id=\"7663032\" target=\"_blank\">",
"        7663032",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McAuley JW and Anderson GD, &ldquo;Treatment of Epilepsy in Women of Reproductive Age: Pharmacokinetic Considerations,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2002, 41(8):559-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/12102641/pubmed\" id=\"12102641\" target=\"_blank\">",
"        12102641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meek PD, Davis SN, Collins DM, et al, \"Guidelines for Nonemergency Use of Parenteral Phenytoin Products: Proceedings of an Expert Panel Consensus Process. Panel on Nonemergency Use of Parenteral Phenytoin Products,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1999, 159(22):2639-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/10597754/pubmed\" id=\"10597754\" target=\"_blank\">",
"        10597754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meierkord H, Boon P, Engelsen B, et al, &ldquo;EFNS Guideline on the Management of Status Epilepticus in Adults,&rdquo;",
"      <i>",
"       Eur J Neurol",
"      </i>",
"      , 2010,17(3):348-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/20050893/pubmed\" id=\"20050893\" target=\"_blank\">",
"        20050893",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nussinovitch M, Soen G, Volovitz B, et al, &ldquo;Urinary Retention Related to Phenytoin Therapy,&rdquo;",
"      <i>",
"       Clin Pediatr (Phila)",
"      </i>",
"      , 1995, 34(7):382-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/7554689/pubmed\" id=\"7554689\" target=\"_blank\">",
"        7554689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeifle CE, Adler DS, and Gannaway WL. &ldquo;Phenytoin Sodium Solubility in Three Intravenous Solutions,&rdquo;",
"      <i>",
"       Am J Hosp  Pharm",
"      </i>",
"      , 1981, 38(3):358-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/7223749/pubmed\" id=\"7223749\" target=\"_blank\">",
"        7223749",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pihlstrom BL, &ldquo;Prevention and Treatment of Dilantin-Associated Gingival Enlargement,&rdquo;",
"      <i>",
"       Compendium",
"      </i>",
"      , 1990, 14:S506-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/2097044/pubmed\" id=\"2097044\" target=\"_blank\">",
"        2097044",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Practice Parameter: Management Issues for Women With Epilepsy (Summary Statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1998, 39(11):1226-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/9821989/pubmed\" id=\"9821989\" target=\"_blank\">",
"        9821989",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabinowicz AL, Hinton DR, Dyck P, et al, &ldquo;High-Dose Tamoxifen in Treatment of Brain Tumors: Interaction With Antiepileptic Drugs,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1995, 36(5):513-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/7614929/pubmed\" id=\"7614929\" target=\"_blank\">",
"        7614929",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richard A, Girard F, Girard DC, et al, &ldquo;Cisatracurium-Induced Neuromuscular Blockade is Affected by Chronic Phenytoin or Carbamazepine Treatment in Neurosurgical Patients,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2005, 100(2):538-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/15673889/pubmed\" id=\"15673889\" target=\"_blank\">",
"        15673889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rowden AM, Spoor JE, Bertino JS Jr, &ldquo;The Effect of Activated Charcoal on Phenytoin Pharmacokinetics,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1990, 19(10):1144-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/2221521/pubmed\" id=\"2221521\" target=\"_blank\">",
"        2221521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saito K, Mori S, Iwakura M, et al, &ldquo;Immunohistochemical Localization of Transforming Growth Factor Beta, Basic Fibroblast Growth Factor and Heparin Sulphate Glycosaminoglycan in Gingival Hyperplasia Induced by Nifedipine and Phenytoin,&rdquo;",
"      <i>",
"       J Periodontal Res",
"      </i>",
"      , 1996, 31(8):545-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/8971653/pubmed\" id=\"8971653\" target=\"_blank\">",
"        8971653",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sankar JM, Agarwal R, Deorari A, et al, &ldquo;Management of Neonatal Seizures,&rdquo;",
"      <i>",
"       Indian J Pediatr",
"      </i>",
"      , 2010, 77(10):1129&ndash;35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/20882435/pubmed\" id=\"20882435\" target=\"_blank\">",
"        20882435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shields WD, &ldquo;Status Epilepticus,&rdquo;",
"      <i>",
"       Pediatr Clin of North Am",
"      </i>",
"      , 1989, 36(2):383-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/2648281/pubmed\" id=\"2648281\" target=\"_blank\">",
"        2648281",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Soriano SG, Sullivan LJ, Venkatakrishnan K, et al, \"Pharmacokinetics and Pharmacodynamics of Vecuronium in Children Receiving Phenytoin or Carbamazepine for Chronic Anticonvulsant Therapy,\"",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 2001, 86(2):223-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/11573664 /pubmed\" id=\"11573664 \" target=\"_blank\">",
"        11573664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suzuki Y, Mimaki T, Cox S, et al, &ldquo;Phenytoin Age-Dose-Concentration Relationship in Children,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 1994, 16(2):145-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/8009561/pubmed\" id=\"8009561\" target=\"_blank\">",
"        8009561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Treatment of Convulsive Status Epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1993, 270(7):854-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/8340986/pubmed\" id=\"8340986\" target=\"_blank\">",
"        8340986",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Treiman DM, Meyers PD, Walton NY, et al, &ldquo;A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 339(12):792-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/9738086/pubmed\" id=\"9738086\" target=\"_blank\">",
"        9738086",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verrotti A, Scardapane A, Manco R, et al, &ldquo;Antiepileptic Drugs and Thyroid Function,&rdquo;",
"      <i>",
"       J Ped Endocrinol Metab",
"      </i>",
"      , 2008, 21(5):401-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/18655520/pubmed\" id=\"18655520\" target=\"_blank\">",
"        18655520",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wright PM, McCarthy G, Szenohradszky J, et al, &ldquo;Influence of Chronic Phenytoin Administration on the Pharmacokinetics and Pharmacodynamics of Vecuronium,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2004, 100(3):626-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/15108978/pubmed\" id=\"15108978\" target=\"_blank\">",
"        15108978",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhou LX, Pihlstrom B, Hardwick JP, et al, &ldquo;Metabolism of Phenytoin by the Gingiva of Normal Humans: The Possible Role of Reactive Metabolites of Phenytoin in the Initiation of Gingival Hyperplasia,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1996, 60(2):191-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/48/35594/abstract-text/8823237/pubmed\" id=\"8823237\" target=\"_blank\">",
"        8823237",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9769 Version 53.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-16712FB15A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_48_35594=[""].join("\n");
var outline_f34_48_35594=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11284327\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209593\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209594\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209644\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209598\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209622\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209599\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209600\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209601\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209562\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209547\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11441305\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209567\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209651\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209566\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14960593\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209653\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209642\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209570\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209551\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209639\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209556\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209588\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209558\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209573\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209606\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209574\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209575\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209572\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209560\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209563\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209576\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209550\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209569\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9769\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9769|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/49/7958?source=related_link\">",
"      Phenytoin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=related_link\">",
"      Phenytoin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_48_35595="New daily persistent headache criteria";
var content_f34_48_35595=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    New daily persistent headache diagnostic criteria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         Description:",
"        </strong>",
"        Headache that is daily and unremitting from very soon after onset (within three days at most). The pain is typically bilateral, pressing or tightening in quality and of mild to moderate intensity. There may be photophobia, phonophobia or mild nausea.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Diagnostic criteria:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A. Headache for more than three months fulfilling criteria B through D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B. Headache is daily and unremitting from onset or from less than three days from onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C. At least two of the following pain characteristics:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1. Bilateral location",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2. Pressing/tightening (nonpulsating) quality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        3. Mild or moderate intensity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        4. Not aggravated by routine physical activity such as walking or climbing stairs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        D. Both of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1. No more than one of photophobia, phonophobia or mild nausea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2. Neither moderate or severe nausea nor vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        E. Not attributed to another disorder",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Headache classification subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_48_35595=[""].join("\n");
var outline_f34_48_35595=null;
var title_f34_48_35596="Rx Chlamydia trachomatis";
var content_f34_48_35596=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76844&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment options for chlamydia trachomatis infection and related clinical syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Urethritis, cervicitis, conjunctivitis, or proctitis (except lymphogranuloma venereum)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Drugs of choice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Azithromycin 1 g oral once",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxycycline&bull;&Delta; 100 mg oral twice daily for seven days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ofloxacin&Delta; 300 mg oral twice daily for seven days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Levofloxacin&Delta; 500 mg oral daily for seven days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythromycin&loz; 500 mg oral four times daily for seven days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infection in pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Drugs of choice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Azithromycin 1 g oral once",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amoxicillin 500 mg oral three times daily for seven days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythromycin&loz; 500 mg oral four times daily for seven days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neonatal ophthalmia or pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Drugs of choice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Azithromycin 20 mg/kg oral once daily for three days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythromycin 12.5 mg/kg oral four times daily for 14 days&sect;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lymphogranuloma venereum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Drugs of choice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxycycline&bull;&Delta; 100 mg oral twice daily for 21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythromycin&loz; 500 mg oral four times daily for 21 days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Related clinical syndromes include nonchlamydial nongonococcal urethritis and cervicitis.",
"     <br>",
"      &bull; Or oral tetracycline 500 mg four times daily.",
"      <br>",
"       &Delta; Not recommended in pregnancy.",
"       <br>",
"        &loz; Erythromycin ethylsuccinate 800 mg may be substituted for erythromycin base 500 mg; erythromycin estolate is contraindicated in pregnancy.",
"        <br>",
"         &sect; Pyloric stenosis has been associated with use of erythromycin in newborns.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Drugs for sexually transmitted diseases. Treat Guidel Med Lett 2004; 2:67.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_48_35596=[""].join("\n");
var outline_f34_48_35596=null;
var title_f34_48_35597="Troponin I in unstable angina";
var content_f34_48_35597=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Cardiac troponin I concentration and mortality in unstable angina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 279px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mortality rate at 42 days according to the level of cardiac troponin I measured at baseline in 1404 patients with unstable angina or non-Q wave myocardial infarction. There was a progressive increase in risk with higher troponin levels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Antman EM, Tanasijevic MJ, Thompson B, et al. N Engl J Med 1996; 335:1342.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_48_35597=[""].join("\n");
var outline_f34_48_35597=null;
var title_f34_48_35598="Airway stenosis tomogram";
var content_f34_48_35598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Airway stenosis tomogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 316px; height: 210px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two tomographic images demonstrate focal tracheal stenosis (red arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_48_35598=[""].join("\n");
var outline_f34_48_35598=null;
var title_f34_48_35599="Ultrasound persistent median artery";
var content_f34_48_35599=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1104px;\">",
"  <div class=\"videoplayer\" h264=\"./images/NEURO/76718/US_persist_median_art_conv.mp4?title=Ultrasound+persistent+median+artery\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Ultrasound persistent median artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a real-time axial image of the median nerve (N) at the wrist in a healthy subject with a persistent median artery (A). Note that the nerve and artery are in the same fibrous tissue sheath, as they move together with piano-playing movements of the fingers. The pulsations of the artery are apparent on B-mode and the presence of Doppler signal further confirms pulsatile flow through this structure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Francis O Walker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_48_35599=[""].join("\n");
var outline_f34_48_35599=null;
